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Tenofovir disoproxil fumarate (TDF) is used worldwide for the treatment of HIV-1 infection. Teno-
fovir has been found to be associated with declines in renal function and chronic kidney disease
in HIV-infected patients. There are limited data on how soon after antiretroviral therapy (ART)
initiation any loss of renal function can be detected. We studied a cohort of HIV-infected adults
initiating TDF-containing ART regimens at the Hannan Crusaid Antiretroviral Treatment Centre
in Gugulethu. The centre provides ART to the residents of the Gugulethu and Nyanga districts
situated on the outskirts of Cape Town. We described the prevalence and incidence of renal dys-
function in this cohort, the patterns of change in their renal function in the first 12 months on
therapy and factors associated with renal dysfunction. We also examined the diagnostic value of
early serum creatinine tests in identifying incident renal dysfunction after 12 months.
Methods
All consecutive HIV-infected, adult patients who initiated ART regimens with TDF at Hannan Cru-
said between February 2010 and April 2012 were eligible for the study. Renal function was assessed
for the first 12 months on ART by estimating glomerular filtration rate (eGFR) calculated using the
Cockroft-Gault equation. Creatinine clearance was categorised into normal, mild, moderate and
severe renal dysfunction according to the National Kidney Foundation Kidney Disease Outcomes
Quality Initiative Criteria based on values of eGFR >90, 60-89, 30-59 or <30 ml/min/1.73m2,
respectively. We examined predictors of renal dysfunction using multivariable logistic regression.
Linear mixed effect regression models were used to describe the mean eGFR trajectory over 12
months on TDF, using stratified models for sub-group analysis and maximum likelihood estima-
tion. We used imputed data to assess the usefulness of early serum creatinine tests in predicting
the change in eGFR at 12 months.
PART I presents the study protocol with a brief motivation for the relevance of the study and the
methodology used in the analysis.
PART II presents a structured literature review on HIV and the kidney in the pre- and post-
antiretroviral therapy eras. It provides an overview of empirical evidence on tenofovir and its











PART III summarizes the methodology, results and interpretation of the analysis conducted in
a journal-ready manuscript according to BioMed Central’s AIDS Research and Therapy journal
requirements.
Findings
The cohort consisted of 62% women and 38% men, median age at baseline was 34 years
(IQR 29; 41 years). Most of the patients had normal baseline renal function; eGFR >90 µmol/L
(62%), 34% had mildly impaired eGFR and 4% had moderate-severe renal function impairment.
Age greater than 41 years, female gender, higher WHO stage (III and IV) and anaemia were all
independently associated with increased probability of moderate or severe renal dysfunction at
baseline. The estimated glomerular function improved in most sub-groups of patients over the
first 12 months on TDF (0.960 ml/min/1.73m2 mean increase over 12 months (95% CI: 0.67; 1.26)
and this increase was not significantly confounded by baseline covariates. Female gender, higher
baseline serum creatinine and age greater than 29 years were associated with faster growth in mean
eGFR over 12 months. Overall incidence of eGFR decline over 12 months was low (4.4% developed
eGFR <50 ml/min/1.73m2) and the crude incidence rate for a decline >10 ml/min/1.73m2 in 12
months was 3.60 per 100 person years. Earlier creatinine tests that were done before 4 months on
ART had limited diagnostic value in predicting overall renal function change after a year on ART.
Conclusions
Renal dysfunction was uncommon in HIV-infected adults initiating ART in this primary health care
setting. Renal function generally improved during the first year on ART even in those with lowest
creatinine clearance at initiation. Creatinine tests done earlier than four months after baseline
screening may be unnecessary. This is similar to the results found in previous studies and has
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1. Prevalence and Incidence of Renal Dysfunction in
Patients initiating Antiretroviral Therapy at a
Primary Health Care Centre in Gugulethu, Cape
Town: a Cohort Study
1 Protocol Summary
The South African government included tenofovir disoproxil fumarate (TDF) as a first-line an-
tiretroviral regimen drug in April 2010. Tenofovir is a known nephrotoxin and observational stud-
ies have found tenofovir to be associated with significant, though modest declines in glomerular
function. There are few data on patterns of change in renal function after tenofovir initiation.
The World Health Organization (WHO) recommends that renal monitoring be conducted before
initiation of tenofovir. Patients with compromised renal function and high-risk patients for devel-
oping kidney disease should not be started on tenofovir. In South Africa, the antiretroviral therapy
(ART) guidelines recommend that serum creatinine and creatinine clearance be measured at ART
initiation, at months 3 and 6 and yearly thereafter for patients on tenofovir in order to identify
toxicity. In a primary health care setting, periodic monitoring might be difficult to maintain. In
addition, research has shown that the prevalence of pre-existing kidney disease in HIV-infected
patients is higher than in the general population which poses a significant burden on the health
care system if compounded by the use of tenofovir. We intend to address key questions regarding
the prevalence and incidence of renal dysfunction and patterns of change in renal function in the
first year after initiating tenofovir in a primary health care setting in this analysis.
2 Introduction
2.1 Background
The South African government included tenofovir as a first-line antiretroviral regimen drug in
April 2010 [1]. Tenofovir is a nucleoside reverse transcriptase inhibitor which is widely used in
combination antiretroviral therapy including as a fixed dose combination pill [2]. The first efficacy
and safety trials conducted in HIV-infected patients found tenofovir to be an effective drug with a












afterwards found tenofovir to be associated with a host of renal complications including acute kidney
injury (AKI), renal failure, chronic kidney disease (CKD) and proximal tubular injury [7–12] 1.
Subsequent observational cohort studies have found tenofovir to be associated with significant
but modest declines in glomerular function [2]. A pooled measure from a meta-analysis of 17
studies in 2010 found tenofovir to be associated with a mean decrease in creatinine clearance of 3.9
ml/min/1.73 m2 over the time of treatment exposure [13]. Although it has been established that
tenofovir is related to significant but small loss of renal function, the general consensus is that risk
of nephrotoxicity should not be a reason to withhold treatment since the benefits of highly active
antiretroviral therapy (HAART) may outweigh potential risks. Moreover, renal toxicity resulting
from tenofovir can be reversed after cessation of the drug in acute cases [2, 14]. Early detection
of any nephrotoxic effects and cessation of TDF treatment are therefore important to avoid kidney
damage [15].
The WHO recommends that serum creatinine screening must be conducted before initiation of TDF
and that patients with compromised renal function should not be started on TDF [16]. However,
laboratory monitoring is not a requirement for the initiation of ART and lack of access to laboratory
testing facilities to measure serum creatinine should not be a barrier to TDF use in remote and
resource-limited settings [16]. Nevertheless, the current guidelines emphasize that more data are
needed on whether routine or periodic laboratory monitoring of renal function among TDF users
is required for all individuals or only high-risk patients [17]
High-risk groups identified include those with pre-existing renal disease (also higher serum creatinine
levels prior to starting TDF), advanced HIV disease (acquired immunodeficiency syndrome (AIDS)
and low CD4 counts), age >40 years, low body weight (<50 kg or body mass index (BMI) <18.5
kg/m2), having other risk factors for renal disease like untreated hypertension and diabetes, and
using a protease inhibitor (PI) or other nephrotoxic drugs in addition to TDF [17]. Patients that
fall into these subsets should have their creatinine clearance monitored to detect and limit further
progression of renal impairment [6, 16,18].
It is still not known how early after treatment initiation the loss of renal function can be detected.
Several studies have suggested that changes in the renal function after ART initiation (with or
without TDF) mostly occur during the first year [19]. However, knowing when to screen for
elevated serum creatinine levels within this year would enable optimal monitoring of incident renal
dysfunction in order to detect it early and prevent severe disease. Some studies have suggested that
renal dysfunction can occur as early as during the first two to three months after initiating TDF in
those with normal baseline estimated glomerular filtration rate (eGFR) [18, 20, 21] but there are
1Other complications reported in the literature: Fanconi syndrome, hypophosphatemia, normoglycemic glycosuria,












few data from resource limited settings in sub-Saharan Africa.
The South African National ART guidelines recommend that serum creatinine and creatinine clear-
ance be measured at ART initiation, after 3 and 6 months and annually thereafter for patients on
tenofovir to identify TDF toxicity. A creatinine test and urinalysis should be done and if found to
be abnormal, the patient ought to be referred for specialist opinion [22].
In a primary health care, periodic monitoring might be difficult to maintain, particularly where
there is limited access to laboratory infrastructure [23]. In attempting to scale up ART in resource-
limited settings, simplification of treatment is important for successful implementation of ART
[24]. Evidence from resource-limited settings has shown that TDF implementation without prior
screening of serum creatinine and routine renal monitoring could still be a viable option, especially
in high HIV-prevalence settings where the cost of laboratory monitoring exceeds the benefits [23].
Coupled with this complication is the high prevalence of pre-existing chronic kidney disease in
HIV-infected patients ranging from 5 - 15% of patients presenting with a creatinine clearance
eGFR <60ml/min/1.73 m2 [25, 26]. Overall, both acute kidney injury (AKI) and CKD are more
prevalent in HIV-infected persons than in the general population [27]. The prevalence of HIV-
related kidney diseases varies in sub-Saharan Africa from as high as 34% in Zambia and 20 - 49%
in Uganda, to 6% in South Africa [28]. Fabian et al. report that it is hard to quantify the exact
prevalence due to varying criteria used for diagnosis of kidney disease in patients with HIV across
sub-Saharan Africa [28]. All in all, HIV-infected patients of African descent are at higher risk of
renal disease both within Africa and in the diaspora [28,29].
Our key interests in this analysis are to describe the prevalence of different degrees of renal dys-
function in patients initiating ART in primary health care in South Africa. We are interested in
exploring the risk factors associated with impaired renal function and whether it is possible to
identify high-risk groups at baseline using disease characteristics, instead of laboratory testing.
Our second objective is to describe the incidence of renal dysfunction and patterns of change in
renal function in patients starting tenofovir in the first 12 months on therapy. Thirdly, we want
to determine the diagnostic role of early serum creatinine measures in identifying incident renal












2.2 Rationale and Study Objectives
The following objectives are outlined for the study:
1. To describe the prevalence of different degrees of renal dysfunction in patients initiating
TDF-containing ART regimens both overall and by patient characteristics: demographic
characteristics (age, gender) and HIV disease characteristics (T-lymphocite cell bearing CD4
receptor (CD4) count, WHO staging)
Key question: How common is prevalent renal dysfunction in patients starting ART, and what
factors are associated with this?
2. To describe the patterns of change in renal function in patients initiating TDF-containing
ART regimens, with measures at baseline and after 1, 2, 4 and 12 months on ART by patient
characteristics: demographic characteristics (age, gender) and HIV disease characteristics
(CD4 count, WHO staging)
Key questions: What is the overall pattern of change in renal function among patients starting
TDF? How common is incident renal dysfunction in patients starting TDF (during the first
12 months on therapy) and what factors are associated with this?
3. To examine the diagnostic role of early serum creatinine measures on ART in identifying
incident renal dysfunction
Key questions: What proportion of all incident renal dysfunction detected during the first 12
months on therapy is detected at month 1, 2, 4 and 12? What is the prognostic role of early
changes in serum creatinine in the subsequent detection of renal dysfunction?
3 Methods
3.1 Study Design
This is a retrospective cohort study based on routinely collected clinical data. We will review clinical
data from HIV-infected patients enrolled in a community-based ART program between February













3.2 Population and Sampling
Population
The Gugulethu/Nyanga district has a population of about 420 000, and has the highest prevalence
of HIV in the Western Cape, after Khayelitsha, reported at 29% in 2008 [30]. The majority of
the population is of low socio-economic status, being either unemployed or earning less than R
1000 per month [31]. The Hannan Crusaid Treatment Centre (HCTC) is based at the Gugulethu
Community Health Centre and provides ART to the residents of this district [31,32].
Patients and Data Collection
Patients become eligible for ART according to the South African Antiretroviral Treatment Guide-
lines for 2010 (CD4 count below 200 cells/mm3 irrespective of clinical stage or CD4 count below
350 cells/mm3 in pregnant women and TB co-infected patients, or WHO stage IV irrespective of
CD4 count [1]). If eligible, they are seen twice before initiating ART, at least 4 weeks and at 2
weeks prior to initiation. Thereafter they are seen at scheduled visits at 4 weeks, 8 weeks, 16 weeks
and then at 16-week intervals [33]. Some patients do not initiate treatment at Hannan Crusaid
either due to death, transferring out and other reasons [32]. During the study period, first-line
ART at the HCTC consists of TDF, lamivudine (3TC) and either efavirenz (EFV) or nevirapine
(NVP) [34]. Patients that had started regimens containing zidovudine (AZT) or stavudine (d4T)
prior to 2010 were kept on these regimens unless they had developed any side-effects [34].
Sampling Strategy and sample size
The sample will consist of all consecutive adult patients (>18 years) enrolled in the ART pro-
gramme at the HCTC between February 2010 and April 2012. We will use existing information of
approximately 1800 patients started on TDF at HCTC since 2010 for whom pre-ART and follow
up serum creatinine tests were done.
3.3 Measurement
Outcome of interest and Independent Variables
The main outcome of interest is renal function assessed by glomerular filtration rate which we
will estimate via creatinine clearance. Using the level of serum creatinine (SCr) in the blood, an
individual’s age, weight and sex, a measure of the creatinine clearance can be calculated [35]. The
eGFR will be calculated using the Cockroft-Gault equation (CG) equation [36].












The degree of renal dysfunction will be determined using the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (K/KDOQI) criteria [37]. Severe renal dysfunction is defined
as eGFR <30 ml/min/1.73 m2, moderate renal dysfunction as eGFR of 30-59 ml/min/1.73 m2
and mild renal dysfunction as an eGFR of 60-89 ml/min/1.73 m2. Other variables of interest are
displayed in Table 1.
Table 1.1: List and definition of variables that will be collected in the study
Variables Scale Categorical
Demographics
Age (years) Numerical- continuous (quartile category proportions)
Sex Categorical - binary Male, Female
Weight (kg) Numerical - continuous (quartile category proportions)
Clinical Characteristics
WHO Stage Categorical- ordinal Stages I- IV
CD4 count (cells/mm3) Numerical- continuous <100 cells/mm3
100-200 cells/mm3
≥200 cells/mm3
viral load (copies/ml) Numerical- continuous log(10) <5log; ≥5 log
Haemoglobin (g/dl) Numerical- continuous Anaemia classification:
Hba <11 pregnant women
Hb <12 women
Hb <13 men
Serum creatinine (µmol/L) Numerical- continuous quartile category proportions






3.4 Potential Bias and Confounding
Loss to Follow Up
Patients are regarded as lost to follow up if they are not seen at the clinic for longer than three
months at any time after starting ART [31]. There might be some differential loss to follow up
if more patients with particular characteristics are lost. We will assess this by comparing the
characteristics of patients lost during the study period to those retained.
Survivor Bias
Similarly, the effect of differential attrition might result in a specific cohort of patients being retained
and for whom measurements are available after 12 months. If these patients are different from the
initial baseline sample, our results might not be representative of the average patient’s progression











4. Data Management and Analysis Plan Protocol
characteristics of those known to have died during the study period to those who are alive after 12
months.
Confounding
We will adjust for possible confounding in the analysis for the variables that are available. Due
to the constraints of secondary data, we are unable to collect additional information to assess
renal function apart from serum creatinine measures. We do not know if the patients had other
comorbidities like diabetes or hypertension. We are also unable to assess BMI, which would provide
additional information for a more standardized estimate of creatinine clearance.
4 Data Management and Analysis Plan
A database will be set up for capturing the data to be collected from patient folders. Data from
the central National Health Laboratory Service (NHLS) database will then be matched on patient
id keys with the additionally collected data. Demographic and disease characteristics are mostly
available for all patients at baseline, but a large number of follow-up weights may be missing. We
suspect that the weight measures may be missing at random. Multiple imputation by chained
equations (mice) will be used to impute missing weights in order to include more eGFR measures
for patients with missing data [38]. All statistical analyses will be performed using STATA/SE
version 12 (StataCorp).
4.1 Objective 1
We will explore descriptive statistics at baseline and conduct a baseline analysis of renal dysfunction
in the adult patients screened for ART. We will use Wilcoxon rank-sum tests for comparing medians,
t-tests for means and Pearson chi-square statistics for proportions. Logistic regression will be used
to examine factors associated with renal dysfunction.
4.2 Objective 2
We will describe observed eGFR profiles both overall and within subgroups of patients. In addition,
we will model the mean estimated GFR profile at baseline, month 1, month 2, month 4 and month 12
using linear mixed effect regression models and maximum likelihood parameter estimation (MLE).
Mixed effect regression models take the correlation between repeated measurements for individual
subjects into account [39].
In order to investigate whether the profiles had significantly different rates of change in different
subgroups of patients over time, we will use stratified models and explore the effect of group×time











5. Ethical Considerations Protocol
account for possible confounding. Model diagnostics will be performed after building each model to
check whether the linearity assumption is valid and whether the appropriate covariance structure
was fitted.
4.3 Objective 3
In order to examine the prognostic role of early serum creatinine measures, a second outcome
variable: the change in eGFR from baseline to month 12, will be derived. Using a prognostic
modelling framework, we will determine which early creatinine measurements best predict change
in eGFR. Separate models for change in eGFR will be built using creatinine measurements at month
1, month 2 and month 4 as predictors. The covariates (age, sex, CD4 cell count, WHO Stage and
baseline creatinine) that improve the model fit will be included in these models. All models will be




This is a secondary data analysis. Although no direct participation is required, we will need to
access the records and patient folders of participants. Data collection at the site had been initiated
prior to this study by approval of the Human Research Ethics Committee at the University of Cape
Town (See Appendix A). Permission to undertake the study will be sought from the Desmond Tutu
HIV Centre and staff at the Hannan Crusaid Treatment Centre to access the patient folders and
the NHLS database.
5.2 HIV-positive, vulnerable population
The participants of this study are vulnerable due to their HIV status and may be subject to
stigmatization and discrimination. The information provided will be regarded as sensitive and
privacy and confidentiality will be maintained at all times during the data collection and analysis.
No patient names will be collected and an anonymous patient code, unrelated to the patient’s
personal identity, will be used for data entry. Computer-based records will only be available to the
researchers and data capturers involved in the study through the use of passwords. All paper-based
records will be destroyed on completion of the study.
Although there are no direct benefits to the patients whose data will be used, there is an indirect











6. Stakeholders and Dissemination Strategy Protocol
resources where they are most needed. The future societal benefits of this research by way of
scaling-up and simplifying of ART services outweigh any potential harm that might arise.
6 Stakeholders and Dissemination Strategy
Given the objectives of the research project, the findings of the study are valuable to the existing
service provision of monitoring patients on ART. We believe that the research question is relevant
and will add to the current knowledge and guidelines on screening for toxicities in patients in
similar resource-limited settings. Relevant stakeholders who are likely to be interested in the
findings include the department of health, community-based health care centres running similar
ART programmes, clinicians in every-day practice and research and academic institutions. The
results will be made available by publication in a peer-reviewed journal.
7 Logistics
An outline of the proposed study time is given below:
April 2012 Data collection, data capturing and cleaning
May 2012 Data validation and merging with existent database
June- July 2012 Baseline data exploration, modelling
August- September 2012 Longitudinal data merging, exploration and summary tables
October- November 2012 Abstract and poster preparation of baseline analysis
February- March 2013 Imputation and mixed-effect modelling
April- May 2013 Prognostic modelling
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The advent of highly active antiretroviral therapy (HAART) signified a new era in the treatment
of HIV with significant decreases in HIV-related morbidity and mortality. With the roll-out of new
drugs came a host of new complications associated with antiretroviral therapy (ART). Among these
drugs is tenofovir disoproxil fumarate (TDF) which is currently used in first-line ART worldwide and
across sub-Saharan Africa. TDF is an effective nucleotide analogue reverse-transcriptase inhibitor
(NtRTI) that inhibits HIV replication but is also a known nephrotoxin. It has been found to be
associated with declines in glomerular function and chronic kidney disease in HIV-infected patients.
The aim of this review is to determine the prevalence and the incidence of renal dysfunction in the
general population of HIV-infected patients and in those initiating ART, and particularly TDF-
containing, regimens. We will investigate risk factors for renal dysfunction in relation to HIV.
This requires an exploration of different definitions of renal dysfunction used for classification in
the literature. A review of longitudinal studies that observed HIV-infected patients over time will
be done to explore patterns of change in renal function among patients starting TDF, and to
examine the diagnostic role of periodic serum creatinine tests for patients on ART. A comparison
of various definitions and methods used as well as analytical approaches applied will be done. We
will evaluate the available evidence from both developed and developing settings and identify gaps
requiring further research.
1.1 Literature Search Strategy
We queried the following search engines for any available articles on tenofovir-related renal dysfunc-
tion: PubMed, Google Scholar and Science Direct. The following search terms were used: ’(renal
OR kidney OR nephron*) AND (toxicity OR failure OR dysfunction OR impairment OR reduction
OR reduced) AND (antiretroviral OR ARV OR ART OR haart OR tenofovir OR TDF OR viread












2. Concepts and Definitions Literature Review
2 Concepts and Definitions
2.1 Glomerular Filtration Rate
The central function of the kidneys is to filter metabolic waste products, excess sodium and water
from the blood and to eliminate them from the body [1]. Kidney function can be gauged by
analysing blood samples or urine samples. The glomerular filtration rate (GFR) is the most widely
used and accepted measure of kidney function [2]. It is the rate at which blood passes through the
kidney and is filtered as filtrate (clear filtered fluid) into the renal tubule.GFR varies with age and
sex, but is approximately 120 - 130 ml/min/ 1.73 m2 surface area in adults [3]. The GFR generally
remains constant in a healthy person, but will fall due to disease and other complications [3]. This
is because the ability to excrete waste material and to regulate the volume and composition of body
fluid declines leading to a rise in plasma urea or creatinine which then results in a reduction in the
measured GFR [3].
2.2 Estimating the Glomerular Filtration Rate
Although GFR cannot be measured directly, it can be estimated using the concentration of certain
substances in the blood [2]. One such substance is the fructose inulin. Inulin clearance: the volume
of blood that is cleared of inulin per unit time, is regarded as the gold standard for estimating
GFR [2].
GFR can also be estimated by measuring serum creatinine. In fact, the most widely used measure
of GFR is creatinine clearance (CrCl) [3]. Using the level of serum creatinine in the blood, an
individual’s age, weight and sex, a measure of the creatinine clearance can be estimated. In the
ideal scenario, a 24-hour urine sample would be needed to determine creatinine clearance exactly
[1]. This makes the estimation of GFR time-consuming and inaccurate if 24-hour urine samples
are not obtained. Instead a host of prediction equations have been developed to estimate GFR or
creatinine clearance using serum creatinine and patient characteristics [3].
The Cockroft-Gault equation for creatinine clearance
The Cockroft-Gault equation (CG) was derived in 1976 from a cohort of 290 patients [4]. Using
their age, gender, weight and serum creatinine, a measure of creatinine clearance was derived to
gauge their GFR.
eGFR = 140−Age(years)×Weight(kg)(72× SCr)× (0.85 if female) (2.1)
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clearance values [4].
The Modification of Diet in Renal Disease Equation
The Modification of Diet in Renal Disease Study Equation (MDRD) equation was derived in 1999
from a sample of 1628 patients with chronic kidney disease (CKD) who were part of the Modification
of Diet in Renal Disease study [5]. The equation uses a patient’s age, race and gender to derive
an estimate of GFR
eGFR = 186× SCr−1.154 ×Age−0.203 × (0.742 if female)(×1.21 if black) (2.2)
The MDRD formula was validated in a sample of patients in the MDRD study who also had CKD
and GFR values between 20-60 ml/min/1.73 m2 [5]
A slight difference in the formulae is that the Cockcroft-Gault equation estimates creatinine clear-
ance, while the MDRD estimates glomerular filtration rate directly [4, 5].
The Chronic Kidney Disease Epidemiology Collaboration equation
The Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation was de-
rived in 2009 from a collaboration of clinical studies and data from the National Health and Nu-
trition Examination Survey in the United States (US) between 1999 and 2006. A pooled dataset
consisting of 8254 participants from 10 studies was used to develop the equation and an additional
sample of 3896 participants from 16 studies was used as the validation sample [6].
The equation depends on categories of race, sex and the range of serum creatinine:
GFR = 141×min(Scr/κ, 1)α×max(Scr/κ, 1)−1.209×0.993Age×1.018 [iffemale]×1.159 [ifblack]
(2.3)
where SCr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and
-0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of
Scr/κ or 1.
The CKD-EPI equation was found to be more accurate than the MDRD study equation especially
at high glomerular filtration rates in the validation sample [6]. Ibrahim and Hamzah assessed
use of the CKD-EPI equation in routine clinical care for HIV-infected patients and found similar
results [7].
The prediction equations for GFR give different results depending on the context in which they
are applied. Reid et al. [8] caution that estimated GFR changes have to be interpreted carefully,
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MDRD formulae yield different results and associated risk factors particularly in the context of
HIV-infected adults in Africa who might be underweight and be sensitive to significant weight
changes after introduction of ART [8].
3 Renal Impairment and HIV
Kidney damage as defined by the US National Kidney Foundation is any structural or functional
abnormality of the kidney when the kidneys fail to adequately excrete toxic substances from the
body [1, 2]. In the beginning this may be without decreased GFR, but over time it can lead to
decreased GFR [2]. Indications of kidney damage include abnormalities in blood composition
or urine (proteinuria) or abnormalities seen in kidney biopsy or imaging tests [2]. Renal failure
can be attributed to a range of underlying causes, with some leading to a rapid decline in kidney
function (acute renal failure), while others lead to a more gradual decline in kidney function over
time (chronic renal failure) [1].
A wide spectrum of HIV-associated kidney diseases has been described in case reports and observa-
tional cohorts in the literature since as far back as 1987 [9]. Renal impairment related to HIV can
be acute or chronic, depending on the pathway by which it occurred. HIV-associated nephropathy
(HIVAN) is the most common cause of chronic kidney disease in HIV-infected patients, particu-
larly among African-Americans and others of African descent [10–12]. Other kidney diseases that
occur in HIV-infected patients include mesangial glomerulonephritis, lupus-like glomerulonephri-
tis, allergic interstitial nephritis, crystal-induced nephropathy, acute tubular necrosis and Fanconi
syndrome [13].
There is lack of consensus on the exact mechanism that drives the HIV-renal disease association,
but some hypothesize that it can be caused directly by HIV or indirectly from other pathways like
diabetes, hypertension and drug-related effects [14]. Acute renal failure commonly results from the
toxic effects of antiretroviral therapy, while chronic renal failure can be caused by multiple other
physiological pathways [14].
In a prospective cohort study conducted in ambulatory HIV-infected patients receiving primary
HIV care in the US between 2000 and 2002, Franceschini et al. found an incidence of acute
renal failure (ARF) of 5.9 per 100 person years (95% CI: 4.9, 7.1). Factors associated with ARF
included immunosuppression (defined as CD4 levels below 200 cells/mm3 and viral loads greater
than 10,000 copies/ml), advanced stage of disease (AIDS) and liver-disease associated hepatitis C
virus (HCV) [15]. Patients who experienced ARF were also more likely to have received HAART
previously [15].
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infected patients of 2.8 per 100 person-years (95% CI: 2.41, 3.24). Unlike the first study, the
investigators did not find HCV coinfection, exposure to HAART (with or without tenofovir) and
HIV viraemia to be associated with ARF. Only levels of immunodeficiency and renal function were
independent predictors of HIV-associated ARF [16]. This study and others seem to suggest that
HIV-replication may be a mediator of CKD in patients at advanced disease stage [17].
The prevalence of CKD in HIV-infected patients has been found to be quite high, ranging from
5 - 15% of patients presenting with a GFR less than 60 ml/min/1.73 m2 [18, 19]. Overall, both
ARF) and CKD are more prevalent in HIV-infected persons than in the general population [20].
The prevalence of HIV-related kidney diseases varies in sub-Saharan Africa from as high as 34%
in Zambia and 20 - 49% in Uganda, to 6% in South Africa [21]. Fabian et al. report that it is
hard to quantify the exact prevalence due to varying criteria used for diagnosis of kidney disease
in patients with HIV across sub-Saharan Africa as shown in Table 2.1.
Table 2.1: Prevalence of HIV-related kidney diseases in sub-Saharan Africa
Country Prevalence a
South Africa 6 %
Nigeria 38 %
Ivory Coast 26 %
Tanzania 28 %
Kenya 25 %
Uganda 20- 49 %
Zambia 34 %
a Adapted from results by Fabian and Naicker, 2009
4 HAART and the Kidney
4.1 Nephrotoxicity
Drugs are mainly excreted through the kidney, particularly through the proximal tubule [17]. The
proximal tubule is thus exposed to substantial levels of toxins and may be susceptible to damage
[17]. The increased roll-out of antiretroviral drugs in the HAART era has achieved unprecedented
survival rates in HIV-infected patients, but has also brought a host of new complications [17].
Several antiretroviral drugs before tenofovir including ritonavir-boosted atazanavir (ATV/r), un-
boosted ATV, indinavir (IDV), ritonavir-boosted lopinavir (LPV/r), and other ritonavir-boosted
protease inhibitor (PI/r) drugs, have been associated with chronic renal impairment in HIV-infected
populations with different degrees of pre-existing renal impairment [22, 23]. Tenofovir, the first
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found to lead to damage of the proximal tubule and mitochondrial toxicity resulting in a spectrum
of moderate-to-severe kidney injuries [17,24]. In addition, increased life expectancy of HIV-infected
patients as a result of HAART means that patients are more likely to experience chronic diseases
like hypertension and diabetes which are risk factors for decreased renal function [17].
4.2 Benefits of HAART
HAART may offset and repair the kidney damage caused by HIV infection in patients with severe
immune suppression and renal dysfunction, resulting in a much milder form of renal dysfunction.
Dolin et al. explain that ART suspends the disease process by stopping new rounds of renal cell
infection [12]. Before the advent of HAART, patients would progress to renal failure requiring
renal replacement therapy within weeks of onset [12].
In a longitudinal study conducted between 1988 and 2004, Lucas et al. observed a cohort of
African- American patients before HAART and after HAART and found that the incidence of
CKD decreased in the HAART era while the prevalence increased as the survival rate of HIV-
infected CKD sufferers improved [25]. The ARV regimens analysed in their study included TDF
after 2001. Kalayjian et al. reported similar findings in a US-based cohort study, showing that
HIV-1 viral suppression as a result of HAART helped to improve the glomerular filtration rate [26].
Tenofovir was included in the regimens of many patients in this study but the authors did not
break down HAART by regimen type.
In the African setting, the Development of Antiretroviral Therapy in Africa trial (DART) study
investigators found that there were renal benefits of HAART for patients with mild to moderate
impairment at baseline. These patients experienced the greatest increase in estimated glomerular
filtration rate (eGFR) over 96 weeks [8]. Peters et al. reported a 53% increase in the median
creatinine clearance of HIV-infected patients with renal dysfunction prior to HAART initiation in
the Home Based AIDS Care trial (HBAC) in Uganda after 2 years of HAART 1.
5 Tenofovir and the Kidney
5.1 History, Development and Efficacy Trials
TDF was developed in 2001 by Gilead Sciences and is currently used worldwide as a first-line
antiretroviral therapy drug [24]. TDF is structurally similar to two antiviral nucleotide analogues
cidofovir and adefovir, which are established nephrotoxins [24]. The recommended dosage in
174% of the cohort in the DART trial initiated ART with tenofovir as part of first-line therapy although tenofovir
was not part of routine care in Uganda and Zimbabwe at the time (2003- 2008). HBAC trial participants were
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adults is 300 mg/day [27]. Kearney et al. explain how tenofovir is excreted renally via glomerular
filtration and active tubular secretion which necessitates dose-interval adjustments in patients with
pre-existing renal impairment before starting a TDF-containing regimen [27].
The first efficacy and safety trials conducted in HIV-infected patients found tenofovir to have
a good safety profile with minimal risk [28–31] (See Appendix C for an outline of the trials).
However, several case reports and case series reported afterwards found tenofovir to be associated
with decreased creatinine clearance, renal failure, chronic kidney disease and proximal tubular
injury [17,32–36] 2. Subsequent observational cohort studies have found tenofovir to be associated
with significant but modest declines in eGFR [24]. A pooled measure from a meta-analysis of 17
studies in 2010, found tenofovir to be associated with a mean decrease in creatinine clearance of
3.9 ml/min/1.73 m2 over the time of treatment exposure [37].
Tenofovir toxicity appears to target the proximal tubule leading to mitochondrial toxicity of the
cells in the proximal tubule. Toxicity may either present as proximal tubular dysfunction without
altering renal function, or proximal tubular dysfunction with decreased renal function [24, 38].
However, measures of tubular function have not been reported as extensively as glomerular function
in the literature [24].
Three large cohort studies from the developed world have found tenofovir to be associated with
increased risk of developing CKD defined as an eGFR of less than 60 ml/min/1.73m2 (cohort of
patients from seven large HIV reference centres in France [39]; HIV-infected patients from the
Veterans Health Administration database in the US [40] and a multicenter cohort of ART-naïve
patients from the Center for AIDS Research Network of Integrated Clinical Systems (CNICS)
Cohort in the US [41]). Tenofovir is also associated with an increased risk of AKI that was
observed within a few months of starting tenofovir in patients with predisposing factors [37]. Renal
function was found to recover after discontinuation of TDF, except in cases of CKD [38].
5.2 Guidelines and Recommendations for Use
Frequent renal monitoring and dose adjustment where necessary are the best strategies for effective
tenofovir administration [24]. International guidelines, like those of the HIV Medicine Association
of the Infectious Diseases Society of America recommend that patients on TDF have their serum
creatinine and eGFR assessed at baseline and at routine check-ups every 3 - 4 months thereafter
[42]. In addition, serum phosphate, proteinuria and glycosuria should be measured at least twice a
year in order to test for possible proximal tubular dysfunction [42].
Following evidence on increased toxicities associated with stavudine (d4T), the WHO recommended
2Other kidney complications associated with TDF: Fanconi syndrome, hypophosphatemia, normoglycemic glyco-
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that countries take progressive steps to reduce the use of d4T in first-line regimens. In 2010, the
WHO advised countries to transition towards complete AZT- or TDF-based first-line regimens
in settings where d4T regimens were still the main option for starting ART [43]. In the current
WHO guidelines, TDF is recommended for first-line therapy in combination with lamivudine (3TC)
(or emtricitabine (FTC) + efavirenz (EFV)) or as a fixed-dose combination for treatment-naïve
patients. Prior to the updated World Health Organization (WHO) guidelines for 2013, serum
creatinine screening was recommended before ART initiation and every 6 months when possible [43].
However, laboratory monitoring was and is currently not a requirement for the initiation of ART.
Therefore lack of access to laboratory testing facilities to measure serum creatinine should not be a
barrier to TDF use in remote and resource-limited settings [43]. The new guidelines rather advise
on symptom-directed laboratory monitoring for safety and toxicity as opposed to strict bi-annual
monitoring [44].
TDF is contraindicated in long-term diabetes sufferers, those with uncontrolled hypertension or
renal failure and when the estimated glomerular filtration rate is <50 ml/min/1.73 m2 [44]. If
any altered creatinine clearance is detected after initiation, the TDF dosage can be adjusted or an
alternative regimen started [43, 44]. However, for those that do start treatment with TDF, more
data are needed on whether routine or periodic laboratory monitoring for toxicities (renal and bone
toxicities) is required for all individuals or only high-risk people 3.
Although it has been established that tenofovir is related to significant albeit small loss of renal
function, the general consensus is that fear of nephrotoxicity should not be a reason to withhold
treatment since the benefits of HAART far outweigh the risks. The renal toxicity resulting from
tenofovir can be reversed after cessation of the drug in acute cases, although not in all patients
[24]. Herlitz et al. studied 13 confirmed cases of acute tubular necrosis due to TDF nephrotoxicity
and found that 20 months after discontinuation of tenofovir, almost 50% (6/13) had completely
recovered their baseline renal function [46]. Early detection of any nephrotoxic effects and cessation
of TDF treatment are therefore very important to avoid tubular damage [38].
Several studies have suggested that changes in renal function after ART initiation (with or without
TDF) mostly occur during the first year [17, 47]. Knowing when to screen for elevated serum
creatinine within this year would enable optimal monitoring of incident renal dysfunction in order
to detect it early and treat or prevent severe disease. Some studies have suggested that this can
occur as early as during the first two to three months after initiating TDF in those with normal
baseline eGFR [45,48]. These include studies in sub-Saharan Africa like the Johannesburg cohort
3 High-risk groups identified: those with pre- existing renal disease (also higher serum creatinine levels prior to
starting TDF), advanced HIV disease (acquired immunodeficiency syndrome (AIDS) and low CD4 levels), age >40
years, low body weight (<50 kg or body mass index (BMI) <18.5 kg/m2), have other risk factors for renal disease
like untreated hypertension and diabetes, and are using a PI/r or other nephrotoxic drugs in addition to TDF should
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study [49]. In this cohort of patients with contraindications that prevented them from starting d4T
or AZT-based regimens, a median time to nephrotoxicity after tenofovir initiation of 3.6 months was
found, confirming the importance of the 3-month creatinine clearance screening [49]. In a Senegalese
cohort, during 12 months of treatment, patients on TDF experienced a higher rate of change in
impairment from mild (eGFR 60-90 ml/min/1.73 m2) to moderate (eGFR 30-60 ml/min/1.73 m2)
compared to patients not receiving TDF, which persisted after the first year [50].
5.3 Use and Introduction in South Africa
The South African government added TDF as a first line regimen drug in April 2010 for all new
patients needing treatment, including pregnant women [51]. The South African National ART
guidelines recommend that serum creatinine and creatinine clearance be measured at ART initia-
tion, at months 3 and 6 and yearly thereafter for patients on tenofovir in order to identify toxicity.
A creatinine screening test and urinalysis should be done and if found to be abnormal, the patient
ought to be referred for specialist opinion [52].
The Southern African HIV Clinician’s Society ART guidelines for adults are similar, but advise that
creatinine should be measured at baseline, at months 3 and 6 and then every 6 months. Particular
attention should be given to high-risk patients with concurrent co-morbidities (hypertension or
diabetes), for whom creatinine should also be checked at 1 and 2 months after initiation [53].
The guidelines suggest that renal function can be estimated either by the modified Cockroft-Gault
equation or the modification of diet in renal disease (MDRD) method 4.
In primary health care, periodic monitoring might be difficult to maintain, particularly where there
is limited access to laboratory infrastructure [54]. Bygrave et al. described low levels of toxicity
outcomes observed in a routine programme in rural Lesotho where the cohort of those who devel-
oped a creatinine clearance below 50 ml/min/1.73m2 dropped by less than 10 ml/min/1.73m2 and
subsequently returned above the threshold after HAART. They conclude that a small proportion
of those patients who dropped to levels between 40 and 50 ml/min/1.73 m2 may have been unnec-
essarily switched off TDF if renal function had been rechecked in the interim. The option of TDF
implementation without prior screening of serum creatinine and routine renal monitoring could still
be a viable option in high HIV-prevalence settings where the cost of laboratory monitoring exceeds
the benefits [54].
4 The modified Cockcroft-Gault equation:
creatinine clearance = (140 − age(years)) × ideal weight(kg)
serum creatinine
For women, multiply the total by 0.85.
The guidelines stipulate that the results of these formulae differ slightly but either can be used for clinical management
[53]. We chose to use the Cockroft-Gault formula in section 2.2 because we had weight measurements available and
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6 Observational Studies on Tenofovir Use
Important differences exist in the studies that have explored the effects of tenofovir, both in study
settings, study designs, definitions used and length of follow-up. This makes it difficult to draw
definitive conclusions about the effects of tenofovir use.
Table 2.2 displays different observational studies from established cohorts in developed settings
(Europe, North America and Australia). These studies mostly consisted of patients in long-term
HIV care, with some who were ART-experienced and others completely treatment-naïve (to ART
and TDF), observed over long periods of follow-up. The D:A:D study [23] and the Veterans Health
Administration study [40] each had up to 10 years of follow-up. The least period of observation
was 6 months in the study by Scott et al. in which the short-term effects of TDF use on renal
function were studied [55]. Some important differences in participants were the large proportion
of white male, intravenous drug users [56], and male patients infected through male-to-male sex
[23].
In contrast, Table 2.3 displays different observational studies from resource- limited settings (Thai-
land, Uganda, Zimbabwe, Zambia, South Africa, Senegal, Lesotho and Malawi). The study par-
ticipants were mostly obtained from undergoing trials (Staccato Trial in Thailand [57], DART in
Uganda/Zimbabwe [8], HBAC in Uganda [58], a Senegalese cohort from a clinical trial [50] and a
pooled trial analysis from Malawi [59]). As a result, the study participants were subject to certain
screening and monitoring criteria that may have been different from the underlying HIV-infected
populations in these countries. The HBAC trial excluded participants with severe renal dysfunc-
tion (CrCl <25 ml/min) from the study [58]. In certain settings like Malawi, the participants had
serum creatinine tests done by virtue of being enrolled in the trial despite it being non-routine in
standard care. However, Johnson et al. explain that the participants in their study were drawn
from the general HIV-infected population in Malawi and would not have been excluded based on
comorbidities associated with kidney disease [59].
Most patients were ART-naïve at baseline and were newly initiating ART. As TDF was only
introduced as a first-line drug much later in these settings compared to well-resourced settings
5, the studies had much shorter lengths of follow up and outcomes were assessed after HAART
initiation in general and not just TDF-containing regimens in particular. The longest length of
follow-up was for four years in the Johannesburg cohort which included ART- experienced patients
switched on to TDF (79%) [49]. The majority of participants were female [49,54,59].
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6.1 Methodological Approaches
Definition of Outcome
Different outcomes relating to varying degrees of renal dysfunction were assessed as shown in
Table 2.2. Some studies looked at serum creatinine elevations [15, 61, 62] while others looked at
changes/losses in creatinine clearance or decline in kidney function [48,55,56,63,64]. Scherzer et al.
included proteinuria among the outcomes they assessed [40]. Creatinine clearance and glomerular
filtration rate were assessed by either the Cockroft-Gault or MDRD equations in most studies,
except for the study by Laprise et al. which made use of the CKD-EPI formula [56]. They advise
that the CKD-EPI equation is better suited for routine clinical use in HIV-infected patients as the
MDRD equation may overestimate the severity of renal impairment in HIV-infected patients as
found by Ibrahim et al. [7].
In the studies from the developing world shown in Table 2.3, the assessed outcomes range from
changes in creatinine clearance and glomerular filtration rate, severely decreased glomerular filtra-
tion rate (<30 ml/min/1.73 m2), significant and persistent renal impairment, nephrotoxicity and
death. Renal function was assessed using either the CG equation or the MDRD equation. Most
studies defined grades of eGFR impairment by the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (K/KDOQI) grading scale for normal, mild, moderate and severe im-
pairment [2]. Peters et al. [58], Bygrave et al. [54] and Johnson et al. [59] also binarized renal
function at CrCl <50 ml/min/1.73 m2 and >50 ml/min/1.73 m2 which is the recommended dosage
modification criteria stipulated in the WHO ART guidelines [43, 44]. Franey et al. performed
additional urinalysis in order to detect significant proteinuria and haematuria [65].
Scott et al. [55] and Peters et al. [58] made use of toxicity grading scales to define levels of creatinine
beyond the normal range. These include the Adult AIDS Clinical Trials Group (AACTG) toxicity
grades for Creatinine and the National Institutes of Health Division of AIDS (DAIDS) Table for
grading the severity of adult and pediatric adverse events [66].
Creatinine measures were assessed at varying times either according to standard practice in the
studies conducted under routine care settings or according to study protocol. A baseline creatinine
measure was available in all the studies, either prior to HAART or at initiation. In the stud-
ies were follow-up measures were collected, the time frames used were either weekly or monthly
measurements.
Confounding
Common variables adjusted for in the analyses were demographic characteristics (age, sex and eth-
nicity), clinical characteristics (HIV disease stage, CD4 level, viral load, mode of HIV transmission
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baseline renal function and pre-existing renal risk factors) as well as concurrent ARV use and other
nephrotoxic drugs. Body mass index and information on weight change after initiating ART was
not always available. Although weight and BMI are important variables in assessing renal function,
only a few studies took these variables into account [8, 50, 57–59, 67]. These were mostly studies
from the African setting for which changes in patient weights after ART initiation have a significant
effect on renal function.
6.2 Analytical Approaches
The modelling approaches applied in the studies ranged from survival analysis modelling by Cox
proportional hazards and Kaplan-Meier curves [40,56,61,63,67], generalized linear models (logistic
[61,65], linear [56,58], and Poisson regression models [15,23]), marginal structural models [40] and
generalized estimating equations (GEE) [56].
Apart from survival analysis models in which time to an event was modelled explicitly, only a few
studies utilized a repeated measurement analysis approach despite the longitudinal structure of the
data. Laird et al. [68] in their derivation of mixed models for longitudinal data, stress that in order
to analyse longitudinal data the models must adjust for the relationship between serial observations
on the same measurement unit. The correlation between repeated observations has to be accounted
for in order to derive correct unbiased estimates of effect [69].
Gallant et al. modelled the change in creatinine clearance using a single value computed from
the difference between maximum CrCl within one year after initiation and baseline CrCl [48].
Multivariate least squares linear regression was then used to assess the effect of other covariates
on this change. A similar approach was used by Peters et al. who modelled the change from
baseline to 24 months using general linear regression [58]. Preferably, all available creatinine
measurements should have been incorporated in the analysis. Averaging out measurements and
modelling one single measurement led to a considerable loss of statistical power. Similarly, other
studies compared means and medians at different time points to assess changes in CrCl [54].
Scott et al. compared the mean differences in serum creatinine and CrCl values at baseline and
at subsequent time points (12 and 24 weeks). It is difficult to profile the renal function trajectory
over time by comparing averages, especially in attempting to identify the critical time point when
renal dysfunction sets in.
Gayet-Ageron et al. studied CrCl longitudinally by comparing the average CrCl at different time
periods using Spearman correlations and one-way ANOVA [57]. Others used mixed-effect models
to model the mean profile of eGFR over a given time period. Reid et al. [8] used a random
effects model to model changes in eGFR over 96 weeks on ART. De Beaudrap et al. used latent
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into account [50], while Laprise et al. [56] used GEE logistic regression with an exchangeable
correlation pattern for repeated measures. These modelling approaches enabled them to trace the
complete trajectory of patients with multiple repeated measurements in order to study any effect
there might be of TDF on kidney function over time.
Step-wise model-building procedures were often applied in the studies. Step-wise regression has
been criticized because it leads to biased estimation of regression coefficients. Using step-wise
procedures increases the probability of inappropriately selecting non-confounders in analysis models
and omitting confounders [70, 71]. Important variables may have been omitted due to stringent,
arbitrary p-value cut-off criteria.
To illustrate, Peters et al. [58] and Bygrave et al. [54] relied on step-wise regression to identify
risk factors and variables that were independently associated with their renal outcome. Peters et
al. explain that they sequentially dropped each variable with a p.value >10% in order to build
a parsimonious model. However, they only included variables that they found to be associated
with baseline renal dysfunction in univariate analysis. It is unclear whether they were adjusting for
potential confounders, or blindly trying to build the best parsimonious model, increasing the risk
of inappropriately selecting non-confounders in their model.
Bygrave et al. built multivariate logistic regression models by backwards elimination, despite having
a limited number of baseline variables. They calculated adjusted odds ratios for CrCl ≥50 ml/min
compared to CrCl <50 ml/min and identified risk factors for reduced CrCl. They then used these
associations to develop algorithms for screening baseline creatinine based only on age and CD4
level. They acknowledge that the algorithm development would have benefited from including a
broader range of risk factors [54].
Reid et al. [8] built a predictive model to predict baseline eGFR using backward elimination and
deleting the covariate with the least contribution to the coefficient of determination (R2). However,
even for predictive modelling, the use of step-wise regression procedures leads to inflated measures
of R2 and biased F-statistics [72,73]. Application of step-wise regression is erroneous in its attempt
to find a best-model and has been criticized for the above-mentioned reasons.
Another critical point is how the studies dealt with loss to follow-up and missing values in analysis.
Very few of the studies address this directly. Studies that used the survival analysis approach, like
Cox proportional hazards, automatically censored participants with missing outcomes by nature
of the modelling framework used. Standard regression methods used in statistical packages use
complete-case analysis and simply exclude missing data [74]. This may lead to selection bias if the
cases included in the analysis are different from those excluded due to incomplete data. The study
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from analysis, which they found to be similar [23]. Brennan et al. found that excluding over
400 patients with missing creatinine clearance led to selection bias since CD4 levels were different
for those included compared to those excluded in the analysis. They proceeded by using marginal
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7 Summary of Findings and Interpretation of Literature
7.1 Prevalence and risk factors
In the study conducted by Jones et al. in a European cohort of 4183 HIV-infected patients, renal
dysfunction was rare and mostly attributable to a non-TDF cause [61]. Franceschini et al. also
found that in a US-based cohort of HIV-infected patients in primary care, most cases of acute
renal failure were associated more with opportunistic infections resulting from immunosuppression
than with HAART (including tenofovir) [15]. In a similar US cohort consisting of patients who
had received TDF as part of HAART for at least three months in two clinical practice settings, all
patients with serum creatinine increases within 6 months of using TDF had other medical reasons
for this increase [55].
Advanced immunosuppression (low CD4 count, high viral load, prior AIDS-defining illness) [23,48,
65] and decreased renal function at baseline prior to ART initiation [48, 56, 63] frequently emerge
as strongly predictive variables for impaired baseline renal function and decline over time both in
resource-rich and resource-limited settings [48,65]. Other associated factors include HCV coinfec-
tion [65], diabetes [48, 63], age >40 years [56, 62]), lower weight/ BMI <18 kg/m2 [58, 59], low
haemoglobin and anaemia [49,59]. Female gender was sometimes also found to be associated with
higher risk at baseline [54,58,67].
In the African setting, mild-to-moderate renal impairment was more common with a prevalence of
20% in rural Ugandans prior to ART [58]), 13% in rural Kwazulu Natal (KZN) [65], 74% mild and
23% moderate renal insufficiency in Zambia [67], 30% mild and 5% moderate in the Johannesburg
cohort [49]. Severe renal impairment was less common, ranging from over 1% in rural KZN [65]
to 3% in Zambia [67]. Many of these patients had advanced immunosuppression before starting
treatment [50,54,65].
7.2 Incidence, risk and patterns of change over time
Jones and others have found that TDF is not associated with renal dysfunction more often than
other ARVs [61]. In contrast, Gallant and others found that TDF use was associated with signif-
icantly greater decrease in creatinine clearance compared to other nucleoside reverse-transcriptase
inhibitors (NRTIs) [48]. Both these studies were conducted in resource-rich settings, the UK and
US respectively.
In a study in Senegal more patients on TDF moved from mild (60-90 ml/min/1.73 m2) to moderate
renal impairment (30 - 60 ml/min/1.73 m2) after a year, compared to patients not on TDF with a
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(95% CI: 1.40, 5.37). In the DART 15 trial the incidence of grade 3 or 4 decreased eGFR was 1.7%
for participants on TDF [8]. These changes occurred in a median of 14 weeks after starting ART
(IQR, 4-52 weeks; range, 2-96 weeks).
In Western studies, incidence ranged from 1.3% changes in creatinine clearance and serum creatinine
elevations in ART-experienced patients after starting TDF [55], to a cumulative incidence rate of
a confirmed GFR <70 ml/min of 1.18 per year of TDF use (95% CI: 1.12; 1.25) in patients in the
D:A:D study with normal baseline renal function (eGFR ≥90 ml/min) [23]. It was more difficult
to quantify incidence in terms of movements between grades in developed country studies due to
the occurrence of fewer renal events .
The risk of significant renal impairment after initiating ART depends both on baseline characteris-
tics and on clinical characteristics over time and other comorbidities for kidney disease like diabetes
[48, 63]. Some patients with advanced immunosuppression at baseline improved over time, while
others experienced declines in eGFR [48]. Scherzer et al. conclude that pre-existing renal risk
factors did not appear to aggravate the effects of TDF, with TDF exposure itself independently
related to irreversible risk of proteinuria, CKD and rapid declines in GFR [40]. On the other hand,
De Beaudrap found that those with persistent decrease in GFR did not have different baseline
characteristics from those that did not, apart from impaired immune reconstitution [50]. TDF
had an independent effect on adverse renal function even in person’s without pre-existing baseline
renal impairment and this was not significantly modified by age, HCV, prior AIDS-defining illness
or current CD4 cell count [23].
7.3 Time and detecting changes in renal function
The change in CrCl occurred mostly in the first year of TDF use [56]. In the Johns Hopkins HIV
cohort, change in CrCl was evident after 2 months of treatment and was found to persist for the rest
of the year [48], while there were no significant changes in creatinine clearance in the first 6 months
of TDF use in a similar cohort of patients taking TDF in the US [55]. After observing patients
cared for in routine clinical practice in Spain, Padilla et al. found that renal failure was infrequent
during a 12 month period and TDF was associated with a low risk of mild renal failure [62]. In
another study in Italy, renal function was found to improve after 48 weeks due to HAART-induced
viral load suppression [64].
Similar findings were found in the African setting where renal function improved during follow-
up [54], particularly in severely immunosuppressed patients at baseline, who had the greatest
increases in eGFR over time (after 96 weeks [8], and after 24 months [58]). Results from the
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HBAC cohort 16 in Uganda found that a higher baseline serum creatinine level ( >133 mmol/l), a
weight gain of ≥5kg on HAART, WHO stage IV disease and female gender were associated with
greater improvement in creatinine clearance after 24 months on HAART [58].
Although TDF was found to be associated with a statistically significant decline in CrCl, this was
not found to be clinically significant, at least not enough to discontinue its use [48]. Bygrave et
al. hypothesize that by screening patients in a rural Lesotho clinic, some of the patients whose
creatinine clearance dropped to 40-50 ml/min may have been unnecessarily switched off TDF if
renal function had been rechecked as more than 80% of them actually experienced an improvement
in renal function over time [54].
7.4 Identification of gaps and needs for further research
Prevalence and incidence of renal dysfunction varies according to definitions and methods used
[75]. Severe renal dysfunction was rare in most settings but mild-to-moderate dysfunction was
more common in the African setting.
It is evident that we cannot extrapolate the findings from well-resourced settings to the developing
world. Even within the developed world itself, clear differences in prevalence of kidney disease
are evident. Severe renal dysfunction was rare in both settings, but mild-to-moderate dysfunction
was more common in the African setting. Coupled with the additional burden of diabetes and
hypertension in the African setting and patients initiating ART with more advanced disease, the
incidence of renal impairment associated with tenofovir needs a country-specific lense.
Some studies found TDF to be an independent risk factor for renal dysfunction [40]. Others suggest
that pre-existing renal risk factors are in fact aggravated by TDF to progress to renal failure, while
others argue that the beneficial effects of HAART outweigh these risk factors.
While guidelines stress the importance of monitoring patients receiving TDF for early detection of
renal impairment, there has been some debate about when this should be done if at all. There is no
clear evidence as to when would be the optimal time after the first pre-ART screening. The WHO
consolidated guidelines for 2013 are still not clear on how to best monitor renal function in people
using TDF- containing regimens. Unanswered questions persist on whether toxicity monitoring
should be routine or targeted to high-risk patients [44].
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8 Conclusion
The studies reviewed report diverse populations with various risk factors and renal outcomes.
However, there are limited data on the prevalence of renal dysfunction in patients starting ART in
primary care, and the factors associated with impaired creatinine clearance. There is conflicting
evidence about the change in renal function among patients on tenofovir and little is known about
the incidence of renal dysfunction in patients starting tenofovir during the first year on therapy.
If renal dysfunction can be detected at a particular time point after ART initiation, this can
optimize the use of laboratory monitoring and resources. In settings where resources for laboratory
testing are limited, the associations between decreased renal function and markers of advanced HIV
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Abstract
Background: Tenofovir disoproxil fumarate (TDF) is used worldwide for the treatment of HIV-1
infection. Tenofovir has been found to be associated with declines in glomerular function and chronic
kidney disease in HIV-infected patients. There are limited data on the prevalence and incidence of
HIV-related kidney disease in sub-Saharan Africa. We described the prevalence and incidence of renal
dysfunction in primary health care in a cohort of 1092 HIV-infected individuals initiating TDF. We
analysed the patterns of change in their renal function in the first 12 months on therapy, factors
associated with renal dysfunction and examined the diagnostic role of early serum creatinine measures
in identifying incident renal dysfunction after 12 months on ART.
Results: The cohort consisted of 62% women and 38% men, median age at baseline was 34 years
(IQR 29; 41 years). Most of the patients had normal baseline renal function; eGFR >90 µmol/L (62%),
34% had mildly impaired eGFR and 4% had moderate-severe renal function impairment calculated using
the Cockroft-Gault equation. Age greater than 41 years, female gender, higher WHO stage (III and IV)
and anaemia were all independently associated with increased probability of moderate or severe renal
dysfunction at baseline. The estimated glomerular function improved in most sub-groups of patients
over the first 12 months on TDF (0.960 ml/min/1.73m2 mean increase over 12 months (95% CI: 0.67;
1.26) and this increase was not significantly confounded by baseline covariates. Female gender, higher
baseline serum creatinine and age greater than 29 years were associated with faster growth in mean
eGFR over 12 months. Overall incidence of eGFR decline over 12 months was low (4.4% developed
eGFR <50 ml/min/1.73m2) and the crude incidence rate for a decline >10 ml/min/1.73m2 in 12
months was 9.76 per 100 person years. Earlier creatinine tests that were done before 4 months on
ART had limited diagnostic value in predicting overall renal function change after a year on ART.
Conclusion: Renal dysfunction was uncommon in HIV-infected adults initiating ART in this primary
health care setting. Renal function generally improved during the first year on ART even in those with
lowest creatinine clearance at baseline. Creatinine tests done earlier than four months after baseline
screening may be unnecessary.
The article meets the requirements set out in the Instructions for Authors for the AIDS Research and Therapy Journal, an extract
of these instructions is included in Appendix E of the dissertation. For readability purposes, figures and tables are inserted in the text
of the manuscript rather than appended as required by the Journal. Supplementary materials referred to in the article are included in













Tenofovir disoproxil fumarate (TDF)is prescribed world wide as part of antiretroviral therapy
(ART) for the treatment of HIV-1 infection. The South African government included TDF as
a first line regimen drug in April 2010 [1]. The first efficacy and safety trials conducted in HIV-
infected patients found that tenofovir had a good safety profile with minimal risk [2–4]. However,
subsequent observational studies have found tenofovir to be associated with modest but significant
declines in glomerular function in HIV-infected patients [5]. The severity of this decline has im-
plications for the development of chronic kidney disease and the long-term health of HIV-infected
patients.
Coupled with this is the increased prevalence of pre-existing kidney disease in HIV- infected patients
compared to the general population. Approximately 5-15% of patients present with a reduced crea-
tinine clearance (estimated glomerular filtration rate (eGFR)) of <60 ml/min/1.73m2 pre-ART) [6].
But the exact prevalence of HIV related kidney diseases is hard to quantify due to the use of dif-
ferent criteria for diagnosis and different patient populations [7]. In South Africa, the prevalence
of HIV-related kidney disease is estimated at approximately 6% in ART-naïve out-patients who
present with persistent proteinuria [8] and 27% prevalence of HIV-associated nephropathy in hos-
pitalized patients [9]. But the prevalence of abnormal renal function may be different in a primary
health care setting.
There are limited data on how soon after ART initiation any loss of renal function can be detected.
While frequent monitoring is recommended for patients on TDF, no clear evidence exists on optimal
creatinine screening times. The South African National ART guidelines recommend that serum
creatinine and creatinine clearance be measured at ART initiation to rule out pre-existing disease
and again at 3 and 6 months and annually thereafter in order to identify possible TDF toxicity
[1, 10]. The recommendations draw on evidence from both the developed world and from studies











occurs sometime in the first year [11–13]. The World Health Organization (WHO) recommends
screening for renal impairment prior to treatment with TDF, but this is not mandatory to start
treatment [14,15].
However, the updated WHO guidelines for 2013 are still unclear on whether laboratory screening
and toxicity monitoring after ART initiation should be routine or targeted to high risk groups to
best monitor renal function in TDF patients [15]. High risk patients identified include those who
are older, those with pre-existing renal disease, diabetes, untreated hypertension and those using a
boosted protease inhibitor or other known nephrotoxic drugs [15]. The guidelines emphasize that
more research is required in order to devise a suitable monitoring strategy [14,15].
The objectives of this study were to describe the prevalence and incidence of renal dysfunction in
HIV-infected patients initiating ART in primary health care in South Africa. We explored and
described patterns of change in renal function in patients starting tenofovir in the first 12 months
on therapy and the factors associated with renal dysfunction in these patients. In addition we
examined the diagnostic role of early serum creatinine measures done in the first 12 months on
therapy (at months 1, 2, 4 and 12) in identifying incident renal dysfunction.
2 Methods
2.1 Study Setting
The Hannan Crusaid Treatment Centre (HCTC) is based at the Gugulethu Community Health
Centre situated in the Gugulethu district of Cape Town and provides ART to the residents of this
district. The service has been described in detail before [16–18]. Patients become eligible for ART
according to the South African antiretroviral treatment guidelines (either WHO Stage IV disease
or a CD4 cell count below 200 cells/mm3) [14]. If eligible, they are seen twice before initiating
ART, at least 4 weeks and at 2 weeks prior to initiation. Thereafter they are seen at scheduled
visits at 4 weeks, 8 weeks, 16 weeks and then at 16-week intervals [16].
2.2 Cohort Description
Patient records were reviewed for the first year after starting a TDF-containing ART regimen.











regimens at HCTC containing 300 mg of TDF daily between February 2010 and April 2012. A
total of 1861 patients were screened for ART during the period; we excluded women who were
pregnant at ART initiation, patients who were not treatment-naïve and those who died before
starting ART.
2.3 Measures
Patient information was extracted from patient folders at HCTC and an ongoing electronic database
updated with National Health Laboratory Service (NHLS) diagnostic data. The main outcome of
interest was renal function defined as creatinine clearance after 12 months on ART. This was
assessed by estimating the glomerular filtration rate calculated using the Cockroft-Gault (CG)
equation [19].
Creatinine tests were done before initiating ART, after 1 month, 2 months, 4 months, and again after
12 months on ART. We extended the window around the 12 month interval to capture creatinine
measurements done up to 18 months after initiation in cases where no measurement was available
by 12 months. Patients were regarded as lost to follow up if they were not seen at the clinic for
longer than three months after starting ART.
Severe renal dysfunction was defined as eGFR <30 ml/min/1.73m2, moderate renal dysfunction as
eGFR of 30-59 ml/min/1.73m2 and mild renal dysfunction as an eGFR of 60- 89 ml/min/1.73m2,
according to the US National Kidney Foundation Kidney Disease Outcomes Quality Initiative
(K/KDOQI) criteria [20]. Incident renal function decline was defined as any reduction in baseline
eGFR of more than 10 ml/min/1.73m2 or any movement below 50 ml/min/1.73m2, the threshold
indicated by the WHO as a possible indication of TDF nephrotoxicity [15].
2.4 Study Variables
Demographic characteristics (age, sex) and disease characteristics (CD4 cell count, WHO staging,
and viral load) were collected for 1092 patients included in the analysis. Viral load measurements
were done at pre-ART screening which was done (4-2 weeks) prior to ART initiation. Laboratory
diagnostics (CD4 count, viral load, and serum creatinine) were performed by the NHLS diagnostic
pathology services, while WHO staging and weight measurements were done by health care per-











clinic. Anaemia was classified as haemoglobin <12 g/dL for women, and haemoglobin <13 g/dL
for men.
2.5 Statistical Analysis
Prevalence and associated risk factors
Baseline was defined as the date of ART initiation. The prevalence of moderate or severe renal
dysfunction was estimated at baseline using a prevalence ratio of all those with baseline eGFR
<59 ml/min/1.73m2 as a fraction of the total sample. Risk factors for severe or moderate renal
dysfunction at baseline were identified using logistic regression analysis. Prevalence odds ratios
(POR) were estimated for individual baseline covariates and in the final model controlling for age,
gender, WHO stage and anaemia status.
Patterns of change in eGFR
The mean observed GFR profiles over time were plotted by patient and disease characteristics.
Linear mixed effect models using maximum likelihood estimation were used to model the association
between eGFR profiles over time and relevant covariates. The mean eGFR profiles were modelled
from month 1 in order to avoid circularity between baseline covariates used as independent variables
in the models and in the calculation of the eGFR outcome (baseline weight and serum creatinine).
Stratified models were used to investigate whether mean eGFR profiles had significantly different
rates of change in different subgroups of patients over time.
We used model-based imputation by maximum likelihood estimation in the mixed effect models
to account for missing data. For objective 3, Multiple imputation by chained equations (mice)
was used to impute missing weights in order to include measures for patients with missing data at
month 12 [21]. A detailed outline of the imputation process is included in Appendix 1.2.
Incidence of GFR impairment
Incident renal function decline was estimated using incidence proportions calculated using the
number of cases who experienced a reduction in eGFR below 50 ml/min/1.73m2 over the 12 month
period with available weight and serum creatinine measures. A second estimate of incidence was
calculated using incidence rates per 100 person years for any reduction in eGFR of more than 10











Diagnostic Role of early Creatinine Tests
In order to examine the prognostic role of early creatinine tests, we defined a second outcome
variable: the absolute change in eGFR from baseline to month 12 in ml/min/1.73m2.
Separate models for change in eGFR were built using serum creatinine measurements at month
1, month 2 and month 4 as predictors including baseline covariates. The predictive power of
these models was compared using the coefficient of determination R-squared statistic. Nested
models of serum creatinine measurements at months 1, 2 and 4 were compared to determine which
measurements were relatively more useful in predicting the outcome. The nested models were
compared using the likelihood ratio χ2-squared statistic. All statistical analyses were performed
using STATA/SE version 12 (StataCorp). The study was approved by the Human Research Ethics
Committee at the University of Cape Town.
3 Results
3.1 Baseline Characteristics of Patients initiating TDF
The baseline characteristics of the 1092 patients included in the analysis are shown in Table 3.1.
The cohort consisted of more women than men (62% vs. 38%) and the median age at time of
ART initiation was 34 years (IQR 29; 41 years). Most of the patients had renal function within
the normal range of >90 µmol/L at ART initiation (62%), 34% had mildly impaired eGFR and
4% had moderate-severe renal function impairment. More than half the patients presented with
advanced HIV disease at baseline (43% WHO Stage III and 11% Stage IV) with a median CD4 cell











Table 3.1: Baseline demographic, clinical and laboratory characteristics of 1092 participants stratified
by pre- ART renal function
Variable Normal a Mild b Moderate- severe c Total
Median (IQR) 676 (62%) 368 (34%) 48 (4%) 1092 (100%)
Age (years) Median (IQR) 32 (28; 38) 38 (32; 46) 42 (33; 54) 34 (29; 41)
Age category N (%)
<29 years 227 (33%) 69 (19%) 6 (13%) 302 (28%)
29-34 years 181 (27%) 66 (18%) 9 (19%) 256 (23%)
34-41 years 173 (26%) 97 (26%) 6 (13%) 276 (25%)
>41 years 95 (14%) 136 (37%) 27 (57%) 258 (24%)
Sex N (%)
Male 224 (33%) 172 (47%) 16 (33%) 412 (38%)
Female 452 (67%) 196 (53%) 32 (67%) 680 (62%)
WHO disease stage N (%)
I 176 (27.5%) 65 (19%) 6 (13%) 247 (24%)
II 144 (22.5%) 77 (22%) 6 (13%) 227 (22%)
III 252 (39%) 164 (47%) 26 (57%) 442 (43%)
IV 69 (11%) 41 (12%) 8 (17%) 118 (11%)
CD4 cells/mm3 Median (IQR) 161 (93; 226) 150 (71; 209) 114 (60; 184) 154 (84; 218)
CD4 category N (%)
<100 cells/mm3 156 (27%) 105 (33%) 14 (40%) 275 (30%)
100-200 cells/mm3 215 (37%) 117 (37%) 14 (40%) 346 (37%)
≥200 cells/mm3 204 (36%) 95 (30%) 7 (20%) 306 (33%)
Viral load (log10) copies/ml Median (IQR) 4.68 (4.17; 5.18) 4.82 (4.29; 5.33) 4.74 (4.20; 5.60) 4.74 (4.21; 5.22)
Viral load category N (%)
copies/ml <5 log10 351 (65%) 185 (60%) 21 (60%) 557 (63%)
copies/ml ≥5 log10 189 (35%) 121 (40%) 14 (40%) 324 (37%)
Haemoglobin g/dL Median (IQR) 11.7 (10.3- 13) 11.8 (10.1; 13.1) 10.25 (8.8; 11.55 ) 11.7 (10.1; 13)
Haemoglobin g/dL - Males 12.7 (11.3; 14.0 ) 12.5 (10.8; 13.8) 11.4 (10.1; 11.7) 12.5 (11; 13.9)
Haemoglobin g/dL - Females 11.4 (10.0; 12.5) 11.1 (9.6; 12.2) 9.7 (8.1; 11.3) 11.2 (9.7; 12.3)
Anaemia d N (%) 384 (61%) 218 (62%) 40 (91%) 642 (63%)
Serum Creatinine µmol/L Median (IQR) 59 (52; 68) 72 (64; 81) 87 (77; 105) 64 (56; 74)
Weight kg Median (IQR) 67 (59.4; 76.2) 56.8 (50.7; 64.1) 50.5 (46.7; 56.6) 62.4 (54.4; 71.3)
eGFR ml/min/1.73m2[CG] Median (IQR) e 110.6 (99.5; 130.5) 78.5 (72.4; 84.7) 53.5 (48.2; 56.7) 97.1 (81.8; 116.6)
aNormal: eGFR >90 ml/min/1.73m2
bMild: eGFR 60-89 ml/min/1.73m2
cModerate & Severe: eGFR <60 ml/min/1.73m2
dAnemia status: haemoglobin <12 g/dL for women, and haemoglobin <13 g/dL for men











3.2 Risk factors associated with prevalent renal dysfunction at baseline
In univariate analysis, older age (age >41 years), Stage III and IV disease and anaemia were
significantly associated with increased probability of severe-moderate renal dysfunction (p <0.05).
In a multivariable logistic regression model, age greater than 41 years, female gender, higher WHO
stage (III and IV) and anaemia were all independently associated with increased probability of
moderate or severe renal dysfunction at baseline (p <0.05) (See Appendix Table D.1 for crude and
adjusted model output).
3.3 Follow up measurements and loss to follow up
The patient flow diagram in Figure 3.1 displays the available serum creatinine measures at screening
visits during the first year of treatment. Baseline GFR was estimated for 1092 patients who initiated
a TDF-containing regimen and had a serum creatinine measurement at baseline. By month 1, 44
patients had been lost to follow up for reasons other than death and 9 had died (5%). Serum
creatinine measures for 641 patients were available at month 1 (59%), 697 at month 2 (64%) and
614 measurements were recorded at month 12 (56%).
By the end of the first year, a total of 237 patients had been lost to follow up corresponding to a
retention rate of 78%. Reasons for loss to follow up were either known (patient transfers to other
clinics and reported deaths (10%)) or unknown (90%). The patients who were lost during the first
year on ART had similar age, WHO stage, creatinine and eGFR levels as the retained patients at
baseline (See Appendix Table D.2 for full table). There was a greater proportion of men who were
lost compared to women, and some differences in proportions with respect to CD4 cell count, viral
load category and anaemia. Relatively more of those lost had CD4 cell counts <100 cells/mm3,
detectable viral loads ( ≥ 5 log10 copies/ml) and had anaemia. These proportions were inflated by
the clinical characteristics of patients who died, who were sicker than those who remained in care.
Although, the median baseline weight for those lost to follow up was slightly lower (60.1 kg compared
to 63.2 kg), there was no significant difference in median eGFR or renal function categories. More
importantly, there were no significant differences in baseline characteristics for those patients with
missing creatinine versus measured creatinine for any reason at month 12, except for gender which











Figure 3.1: Patient flow diagram for the first year after tenofovir initiation. The boxes between
the stages represent the numbers lost from care and those that died during each stage.
N = number of patients, LTFU = loss to follow up, Perm defer = Permanent deferrals defined
as patients who did not receive ART for a reason other than pre-treatment death and who were
subsequently excluded from the program. SCr = number of serum creatinine measurements
(See Appendix Table D.5 for full table).
3.4 Observed changes in eGFR over time
We explored eGFR profiles by patient demographic and disease subgroups as displayed in Figure
3.2. Panel 2.A displays the overall eGFR profile over the 12 month period with point-wise confidence
intervals for the monthly estimates. The plot displays an increasing linear trajectory which shows
that overall, renal function improved on average in the 12 months after ART initiation.
The additional panels (B-F) display the observed eGFR profiles by age groups, gender and baseline
disease characteristics. Some notable eGFR profile differences exist between age groups, gender,
WHO disease stage and anaemia status at baseline. On average, the age groups had similar slopes
except the oldest age group (age >41 years) which had lower mean eGFR compared to the other
three groups. Women had higher mean eGFR than men, and their eGFR increased at a faster rate
over time. Mean eGFR increased steadily for WHO stage III and IV disease patients. Patients with















Figure 3.2: Profile plots of mean estimated creatinine clearance values (y- axis) and time on TDF in months
(x-axis) by patient demographic and clinical characteristics: A- overall average profile, B- by age group, C-











slopes after month 4. Patients with anaemia had lower mean eGFR levels compared to patients
with no anaemia but the profiles were parallel indicating no significant group effect over time. The
mean profiles for baseline CD4 cell count levels overlap, indicating no significant group differences
between CD4 cell count categories.
3.5 Estimated glomerular function changes over 12 month period
The estimated glomerular function displayed a positive trend over time; eGFR increased by 0.960
ml/min/1.73m2 for every one month increase as shown in Table 3.2 (95% CI: 0.67; 1.26). There
was a negative association with baseline serum creatinine and age. On average, for every µmol/L
increase in baseline serum creatinine, mean eGFR decreased by 0.277 ml/min/1.73m2 (95% CI:
-0.381; -0.172). For every 10 year increase in age, mean eGFR decreased by 12.50 ml/min/1.73m2
(95% CI: -14.68; -10.33). There was a positive association with baseline weight and CD4 cell count.
For every 10 kg increase in baseline weight, mean eGFR increased by 12.2 ml/min/1.73m2 (95%
CI: 10.9;13.6).
The average eGFR estimates for the reference categories at month 1 are displayed in Table 3.2
for those categories. The estimates for the other categories are relative changes compared to
the reference category. Women had higher mean eGFR profiles than men (12.72 ml/min/1.73m2
higher at month 1 (95% CI: 7.97; 17.47 unadjusted). Patients with anaemia had lower mean eGFR
compared to patients with normal haemoglobin levels, while WHO stage III and IV disease patients
had lower mean eGFR profiles compared to stage I and II patients. The mean eGFR profiles for
patients with CD4 cell counts greater than 100 cells/mm3 were higher than those for patients with
CD4 cell counts below 100 cells/mm3.
After adjusting for baseline serum creatinine, baseline weight, age, sex and baseline CD4 cell count,
the adjusted slope estimate showed that the mean effect over time was not significantly confounded
by baseline covariates and eGFR improved in most subgroups of patients over the first 12 months
on TDF (See Table 3.2).
3.6 Stratified Models
The stratified models displayed in Table 3.3 show estimated rates of growth in eGFR in different











Table 3.2: Linear mixed model results for estimated glomerular filtration rate over time
Variable a Model coefficient b 95 % CI c Model coefficient d 95 % CIc
& group intercept & group intercept
Month (continuous) 0.960 ( 0.665; 1.255) 0.926 ( 0.630; 1.221)
Baseline creatinine µmol/L (cont) -0.277 ( -0.381; -0.172) -0.272 ( -0.352; -0.193)
Creatinine category
≤56 µmol/L reference 112.836 (108.400; 117.272)
56- 64 µmol/L -12.479 (-18.806; -6.151)
64- 74 µmol/L -14.732 (-20.926; -8.537)
>74 µmol/L -23.520 (-29.733; -17.307)
Baseline weight (kg)(cont) 1.224 ( 1.093; 1.355) 1.256 ( 1.137; 1.375)
Weight category
≤54.5 kg reference 82.121 ( 78.025; 86.217)
54.5- 62.9 kg 13.268 ( 7.632; 18.904)
62.9- 72.3 kg 19.760 ( 14.258; 25.262)
>72.3 kg 43.751 ( 37.985; 49.518)
Age (years) (cont) -1.265 ( -1.500; -1.030) -1.238 ( -1.426; -1.050)
Age category
≤29 years reference 110.910 (106.546; 115.274)
29- 34 years -2.673 ( -8.692; 3.346)
34- 41 years -12.409 ( -18.502; -6.316)
≥41 years -28.098 ( -34.195; -22.000)
Sex (female) 12.723 ( 7.975; 17.472) 1.988 ( -1.717; 5.693)
Anaemia -5.514 (-10.460; -0.567)
Baseline CD4 cells/mm3 (cont) 0.027 ( 0.003; 0.051) -0.004 ( -0.021; 0.012)
CD4 category
<100 cells/mm3 reference 96.374 ( 91.790; 100.958)
100-200 cells/mm3 6.128 ( 0.179; 12.077)
≥200 cells/mm3 5.272 ( -0.977; 11.520)
WHO Stage (III & IV combined) -3.791 ( -6.180; -1.401)
aNOTE: All models are linear mixed effect models with time as a fixed effect and subjects as random effects
starting at month 1
bUnivariate Analysis; slope coefficient for model with month and intercept relative to the mean for indicated
reference group
c95 % Confidence Interval
dMultivariate Analysis adjusting for baseline covariates shown; coefficients for model with month and baseline











detect differences in the rates of growth between the groups.
The slopes suggest possible differences in the rates of growth in eGFR for different levels of baseline
creatinine, gender, age and baseline CD4 cell count where the degree of overlap of the groups’
confidence intervals showed some differences. Patients with age greater than 29 years experienced
a faster increase in eGFR compared to younger age groups. Women experienced a faster increase
in eGFR over 12 months compared to men. Patients with CD4 cell counts ≥200 cells/mm3 at
baseline experienced faster growth in mean eGFR compared to lower CD4 cell counts. There was
insufficient power to detect differences in the slopes for baseline weight category, anaemia status
and WHO disease stage.
Table 3.3: Linear stratified mixed models for estimated glomerular filtration rate over time
Variable a Month Slope 95 % CI
Coefficient
Month (cont) 0.960 (0.665; 1.255)
Baseline creatinine category
≤56 µmol/L 1.205 (0.454; 1.956)
56- 64 µmol/L 1.272 (0.751; 1.793)
64- 74 µmol/L 0.603 (0.110; 1.096)
>74 µmol/L 0.808 (0.315; 1.301)
Baseline weight category
≤54.5 kg 0.655 (0.0968; 1.213)
54.5- 62.9 kg 1.107 (0.568; 1.647)
62.9- 72.3 kg 0.834 (0.288; 1.380)
>72.3 kg 1.072 (0.432; 1.712)
Age category
≤29 years 0.710 (0.0315; 1.388)
29- 34 years 1.011 (0.367; 1.655)
34-41 years 1.121 (0.623; 1.620)
≥41 years 0.937 (0.510; 1.365)
Men 0.247 (-0.104; 0.598)
Women 1.329 (0.922; 1.735)
No anaemia 1.081 (0.579; 1.582)
Anaemia 0.948 (0.570; 1.327)
CD4 category
<100 cells/mm3 0.946 (0.382; 1.510)
100-200 cells/mm3 0.883 (0.326; 1.440)
≥200 cells/mm3 1.265 (0.772; 1.758)
WHO Stage (I & II combined) 0.946 (0.496; 1.396)
WHO Stage (III & IV combined) 0.871 (0.474; 1.268)











3.7 Incidence of GFR impairment
The proportion of patients who experienced deteriorated renal function below 50 ml/min/1.73m2
over 12 months was approximately 4.4% (seven people by month 1, four people by month 2 and two
people by month 4 of a subset of 293 patients). Using a more sensitive criterion of any reduction
in eGFR of more than 10 ml/min/1.73m2 from baseline eGFR, the incidence rate decreased from
79.31 per 100 person years in month 1 to 9.76 per 100 person years at month 12. Table 3.4 displays
the results.
Table 3.4: Incidence of reduced renal function
Baseline Month 1 Month 2 Month 4 Month 12
Reduced eGFR a 69 76 79 33
LTFU b 5 47 91 46
Persons at risk (N) 1044 1039 992 901 855
Person time (in months ) 1044 1046.5 2125 4059
Person time (in years) 87 87.21 177.08 338.25
Incidence rate (per 100 person years))c 79.31 87.15 44.61 9.76
aPatients with eGFR at least 10 ml/min/1.73m2 less than baseline eGFR
b Patients lost to follow up
cIncidence calculated between time intervals using interval censoring method
3.8 Early Serum Creatinine Measures as Predictors of eGFR at Month 12
Table 3.5 displays the results of the linear regression models for predicting change in eGFR at
month 12 compared to baseline using the imputed data. For the total follow-up visits over 12
months, 55.8% of the weight measures were missing. The univariate model R2 value showed that
and 3% of the variation i change in eGFR at month 12 was explained by the change in creatinine
from baseline to month 1, 17% by change in creatinine from baseline to month 2 and 31% by change
in creatinine from baseline to month 4. Adding more baseline covariates increased the predictive
power of the models by almost 25% as shown in the increase in the multivariate R2. The likelihood
ratio tests comparing the nested models showed that serum creatinine measurements at months 1
and 2 are not as useful in predicting eGFR change after 12 months compared to month 4. Month











Table 3.5: Linear models for continuous change in eGFR at month 12
Variable Univariate a 95% CI b R2 Multivariate c 95% CI R2 χ2 P.valued
Estimate Estimate
SCr Month 1 e -0.384 (-0.574; -0.193) 0.0276 -0.131 (-0.429; 0.167) 0.221 0.1785
SCr Month 2e -0.317 (-0.496; -0.138) 0.174 -0.198 (-0.484; 0.089) 0.292 0.0844
SCr Month 4e -0.534 (-0.773; -0.295) 0.308 -0.656 (-1.188; -0.123) 0.387
aUnivariate estimated coefficient for serum creatinine measure at indicated month
b95% confidence interval (CI)
cMultiple regression estimated coefficient for model including age, sex, baseline weight, baseline serum
creatinine, CD4 category, baseline haemoglobin and WHO disease stage
dChi-squared likelihood ratio test p-value for comparison of models with SCr 1 or SCr 2 additional to
SCr 4
eSerum creatinine (SCr) at the indicated month
4 Discussion
The prevalence of moderate-severe renal dysfunction in patients initiating ART in this primary
health care centre was low (4%). Decreased renal function was associated with increased age,
female gender, more advanced HIV disease stage and lower haemoglobin. Incident reduction in
renal function of more than 10 ml/min/1.73m2 was rare (16.3 per 100 person years), with very
few patients reaching the 50 ml/min/1.73m2 threshold at which switching is advised by WHO
guidelines [15]. The creatinine test at month 4 was more predictive of renal function after 12
months compared to earlier tests conducted at months 1 and 2.
Renal function generally improved over the first year on ART with no significant confounding by
baseline variables (age, sex, baseline weight and serum creatinine, anemia, WHO stage or CD4 cell
count). There were significant differences in the eGFR growth trajectories of patient subgroups
with a faster rate of increase in mean eGFR in those with higher baseline serum creatinine, age
greater than 29 years, CD4 cell counts ≥200 cells/ mm3 at baseline and in women. There might
be modification in eGFR growth by baseline characteristics over time, but our models were not
suitably powered to test this and the clinical significance of the small variations observed here is
uncertain.
A previous study in rural Uganda found similar results in a cohort of patients in the Home-Based
AIDS Care clinical trial Home Based AIDS Care trial (HBAC) [22]. Before ART initiation, 20% of











(HAART) they experienced the greatest improvements in renal function with a 53% increase in their
creatinine clearance. Similar factors were found to be associated with improvements in creatinine
clearance on HAART; higher baseline serum creatinine, female gender and a WHO stage IV disease
status [22].
The prognostic model for the change in eGFR using early creatinine measurements had low pre-
dictive power, but the results were in line with those from a similar primary care setting. Brennan
et al. found that in a Johannesburg cohort of patients on TDF, the 3 month creatinine clearance
was crucial for detecting nephrotoxicity [13]. This suggests that early creatinine measures done at
3-4 months after initiation are important for picking up patients who are at risk of experiencing
deteriorating renal function. Earlier creatinine clearance measures done at 1 or 2 months after
initiation are less predictive of change in renal function after a year on ART.
The same risk factors for renal dysfunction at baseline emerged as found in previous studies from
sub-Saharan Africa: low haemoglobin /anaemia [23, 24], older age and lower CD4 levels [25, 26].
However, we found that female gender had a higher odds of renal dysfunction at baseline, but also
showed greater improvement in renal function over time. Some studies have found the converse,
showing that male gender is associated with greater risk of significant renal impairment [24,26].
Our study had several limitations. Firstly, tenofovir is mainly excreted through the proximal tubule,
which potentially leads to tubular dysfunction [5,27]. However, we were unable to asses this in our
study as neither proteinuria nor glycosuria were assessed by urinalysis. Another major factor we
were unable to assess was the prevalence of other non-communicable diseases correlated with kidney
failure, including diabetes mellitus, hypertension and cardiovascular disease [28]. Considering the
high prevalence of hypertension and cardiovascular diseases in South Africa, it is possible that the
change in kidney function was confounded by these associated conditions [29]. Confounding by
these conditions could lead to a mixing up of the true effect of TDF, attenuating the true increase
in mean eGFR. Moreover, patients that experienced renal impairment might have had other co-
morbidities that put them at increased risk of renal impairment unrelated to TDF exposure.
Our data may have been prone to selection bias, particularly since participants who were lost to
follow up had different risk factors at baseline that may have predicted their probability of being











and have anaemia at baseline. Closer inspection revealed that some of these patients were those
who died during the 12 month period as a result of disease complications. However, they generally
had the same renal function at baseline compared to those who were retained and did not differ
significantly in serum creatinine levels.
The setting is a well-researched clinic with patient records that are maintained regularly. This
allowed access to a large sample of ART-naïve patients with available weight and creatinine measures
recorded after a year on ART. Moreover, the serum creatinine screening policy in this clinic is
different from the National Department of Health standards, with more frequent screening tests
during the first year of ART initiation. This allowed for a closer examination of early changes in
renal function after months 1 and 2 on ART; times that these measures are not usually available
in routine settings in South Africa.
Another strength of our study lies in the fact that we did not exclude those with missing weights.
We used multiple imputation to derive an estimate of weight for all participants for whom serum
creatinine tests were done at subsequent visits. We assumed that the weights were missing at
random as there was no indication that there was informative censoring. By using the Cockroft-
Gault equation we took the influence of weight changes after ART initiation into consideration
giving a more robust measure for monitoring kidney function.
Our results highlight that tenofovir can be administered safely in a primary health care setting
after the initial pre-ART screening of creatinine clearance. Renal function generally improves as
general health improves due to HAART [30]. This contributes to the growing body of evidence in
support of less restriction on tenofovir use in settings where frequent monitoring of renal function
might be difficult or impractical [31].
Given the low prevalence of renal dysfunction before ART initiation, the identified risk factors are
important for monitoring purposes and planning ART services. It is still not clear whether frequent
toxicity monitoring is necessary for all patients on tenofovir. Developing a suitable prognostic tool
can help to limit the pool by identifying high risk patients without requiring costly laboratory
tests. A more cohesive collection and analysis of associated variables on related comorbidities and












In conclusion, this analysis indicates that renal dysfunction appears uncommon in HIV-infected
adults initiating ART in a primary health care setting. In this group of patients without pre-
existing glomerular disease, renal function generally improved during the first year on ART even in
those with lowest creatinine clearance before initiation. Furthermore, creatinine tests done earlier
than four months after baseline screening may be unnecessary. The benefits of tenofovir initiation
potentially outweigh the nephrotoxic effects it might have at least during the first 12 months of
use.
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Efficacy and Safety trials











Table C.1: Safety and Efficacy trials
Trial+ Authors
GS-97-901: Barditch-Crovo, P. &
Deeks, S. G. 2001
GS-98-902: Schooley, R. T. &
Ruane, P. 2002
GS-00-907: Gallant, J. E. &
Staszewski, S.2004
Nelson, M. R. & Katlama, C.2007 Gallant, J. E. & Winston, J. A.:2008
Study
Phase I/II trial of the
pharmacokinetics, safety, and
antiretroviral activity of tenofovir





results from a 48-week,
randomized, double-blind study
Efficacy and safety of tenofovir DF
vs stavudine in combination
therapy in antiretroviral- naive
patients: a 3-year randomized trial
(GS 903). The primary
registrational trial for TDF.
The safety of tenofovir disoproxil
fumarate for the treatment of HIV
infection in adults: the first 4 years
The 3-year renal safety of a tenofovir
disoproxil fumarate vs. a thymidine





AIDS 16(9): 1257-1263 JAMA 292(2): 191-201 AIDS 21(10): 1273-1281 AIDS 22(16): 2155-2163
Countries,
participants & year of
analysis
Eligible subjects: men and women
with HIV-1 infection, HIV-1
RNA> 10,000 copies/ml, CD4≥
200 cells/mm3, sCr level ≤1.5
mg/dl, calculated CrCl rate ≥60





plasma HIV-1 RNA 400-100,000
copies/ml & stable ART (≥ 8
weeks)
81 centers in the United States,
South America, and Europe from 9
June 2000, to 30 January 2004 in
ART-naive HIV-infected patients.
Patients enrolled in the TDF EAP 1
from March 2001 to March 2004,
HIV-positive, with advanced disease and
limited treatment options. Participating
countries: Australia (654), Belgium
(348), Canada (1761), France (1857),
Germany (411), Ireland (12), Italy (553),
the Netherlands (256), Portugal (58),
Spain (576), United Kingdom (819), and
the United States (3038). Plus safety
data from the manufacturer’s database;
reports of all postmarketing adverse drug
reactions received up to 30 April 2005.
ART-naive HIV-infected patients (from
Studies 903 and 934); baseline sCr <1.5
mg/dl, serum phosphorus ≥2.2 mg/dl
and calculated CrCl ≥60 ml/min (for
Study 903) and ≥50 ml/min (for Study
934)using CG equation.
Objective(s) of study
To evaluate the anti-HIV-1
activity, safety, tolerance, and
pharmacokinetics of oral TDF
when administered as a single
daily dose for 28 consecutive days.
To evaluate the safety and efficacy
of once daily doses of TDF
administered in combination with
other antiretroviral therapy (ART)
To evaluate the efficacy and safety
of TDF compared with stavudine
in ART-naive patients.
To characterize the safety profile of TDF
for the treatment of HIV infection in
adults over the first 4 years of use using
data from SAE reports to detect signals
of new safety events not observed in
clinical trials and to explore changes in
patterns of known safety events.
To assess the renal safety of TDF using
data from over 1000 patients, thereby
providing greater power to detect renal









placebo-controlled trial (Phase III)
Analysis of TDF expanded access
program (EAP) and Postmarketing
SADR 2 data
2 clinical trials (RCTs from Studies 903
and 934)
Number of subjects 49 189 602 10 343 1111
Intervention/
exposure
TDF (4 doses): 75 mg, 150 mg,
300 mg, 600 mg
TDF 75 mg, 150 mg, or 300 mg or
placebo to existing ART
TDF (n = 299) in combination
with lamivudine and efavirenz
TDF in expanded access and SAE 3
reports from manufacturer’s database
TDF (n= 556)
Comparison Placebo Placebo
Stavudine (n = 303), with placebo,
in combination with lamivudine
and efavirenz.
all patients were treated with TDF
Thymidine analogue-containing (control)
regimens (n=555) either stavudine or
zidovudine in combination with efavirenz
and either lamivudine or emtricitabine
continued . . .
1Expanded Access Program











. . . continued
Trial+ Authors
GS-97-901: Barditch-Crovo, P. &
Deeks, S. G. 2001
GS-98-902: Schooley, R. T. &
Ruane, P. 2002
GS-00-907: Gallant, J. E. &
Staszewski, S.2004
Nelson, M. R. & Katlama, C.2007 Gallant, J. E. & Winston, J. A.:2008
Duration 4 weeks 48 weeks 144 weeks
4 years since start for SAE reports, but
different mean duration of treatment in
the EAP, United States (13 weeks),
European Union/Australia (24 weeks),
Canada ( 29 weeks).
144 weeks, 3 years
Health outcomes
measured
Signs, symptoms, and laboratory
abnormalities recorded by using a
modified graded toxicity scale 4.
Toxicities or abnormalities
classified as: mild, grade I;
moderate, grade II; severe, grade
III; possibly life threatening, grade
IV.
Efficacy analyzed by the mean
changes in HIV-1 RNA levels
(log10 copies/ml plasma) from
week 0 to weeks 4, 24, and 48.
Safety analyzed by incidence of
grade 3 or 4 clinical and laboratory
adverse events.
Proportion of patients with HIV
RNA levels of less than 400
copies/mL at week 48
any post drug SAE
Abnormalities in serum creatinine (sCr)
(>1.5 mg/dl); serum phosphorus (<2.0
mg/dl); urine proteinuria ≥ 100 mg/dl;
median change from baseline to week 144
in glomerular filtration rate by CG and
by MDRD. Changes from baseline
through week 144 in sCr, serum
phosphorus and urine protein. The
proportions of patients developing a
maximum graded toxicity in sCr, serum





No renal abnormalities at 28 days.
Grade III or IV adverse events
were limited to laboratory
abnormalities, including elevated
creatine phosphokinase and liver
function tests, which resolved with
or without drug discontinuation
and without sequelae. In summary,
oral tenofovir DF exhibits a
pharmacokinetic profile that
supports once-daily dosing. With
good antiviral potency and
tolerability.
The incidence of adverse events
was similar among the TDF groups
and placebo through week 24.
Throughout the 48-week study, no
significant changes in renal
function were observed. In
treatment-experienced patients
with baseline nucleoside resistance
mutations, TDF provided
dose-related, durable reductions in
HIV-1 RNA. Through 24 weeks,
the safety profile of TDF was
similar to that of placebo.
The number of bone fractures and
the renal safety profile were similar
between the 2 groups. Through 144
weeks, the combination of TDF,
lamivudine, and efavirenz was
highly effective and comparable
with stavudine, lamivudine, and
efavirenz in antiretroviral-naive
patients. TDF appeared to be
associated with better lipid profiles
and less lipodystrophy.
Serious adverse events (SAEs) were
reported in 631 (6%)of patients enrolled
in the EAP. A renal SAE of any type was
observed in 0.5% of patients, and graded
elevations in sCr occurred in 2.2% of the
patients studied.Significant baseline risk
factors for development of nephrotoxicity
identified in multivariate analysis were
elevated sCr, simultaneous use of
nephrotoxic medications, increased age,
lower weight, and lower CD4 cell count
of which preexisting kidney disease,
nephrotoxic medications, and older age
are known risk factors for renal disease.
For postmarketing safety data the most
commonly reported SADRs 5 were renal
events. In summary, The most common
SADRs reported for TDF were renal,
including renal failure, FanconiâĂŹs
syndrome, and sCr increase, but an
overall favorable safety profile for TDF
demonstrated in the treatment of adults
with HIV infection in expanded access
and postmarketing safety surveillance.
Small but statistically significant
decreases in estimated GFR were
observed in the TDF group through 144
weeks. A significant increase in GFR was
seen in the control group using both
formulae. But no clinically relevant renal
disease, adverse events or changes in sCr
and phosphorus were seen with both the
TDF and control groups in ART-naive
patients in 144 weeks. The incidence of
sCr elevation or hypophosphatemia was
less than 1% in both treatment groups.
Likewise, a similar incidence of
proteinuria (5âĂŞ6%) was seen in both
treatment groups.
4based on the AIDS Clinical Trials Group common toxicity grading scale













1.1 Fraction of missing data
Patterns of missingness in the data: 319



















Not all patients had weight measurements at all five time points. We assumed a missing at random
structure, i.e. missing weights were dependent on the observed data but not on missing character-
istics as defined by Rubin 1 and used mice to impute missing weights.
Framework
MICE is a practical approach used to create imputed datasets using a set of imputation models,
with one model for each variable with missing values.
Let complete data Y be a partially observed random sample from a p-variate multivariate distri-
bution P(Y|θ) where θ is a vector of unknown parameters. The aim is derive the multivariate











distribution of θ, either explicitly or implicitly. The chained equations algorithm is designed to
obtain the posterior distribution of θ by sampling iteratively from conditional distributions of the
form P (Y1|Y−1, θ1) . . .P (Yp|Y−p, θp) 2.
The process starts with a simple draw from observed marginal distributions and the t-th iteration
of chained equations is a Gibbs Sampler that successively draws from:
θ
∗(t)
1 ∼ P (θ1|Y obs1 , Y
(t−1)





1 ∼ P (Y1|Y obs1 , Y
(t−1)






θ∗(t)p ∼ P (θp|Y obsp , Y
(t)
1 , . . . , Y
(t)
p−1)
Y ∗(t)p ∼ P (Yp|Y obsp , Y
(t)





where Y (t)j = (Y obsj , Y
∗(t)
j ) is the jth imputation of the missing variable at iteration t.
Model
For our third objective, mice was used to impute missing weights in STATA (version 12) as described
by White and Royston 3. The imputed data allowed us to include more eGFR measures for patients
with missing data at month 12. We performed the imputation of missing weights using weight
measurements taken at different time points and assuming normality of weights. A detailed outline
of the imputation modeling process is shown below.
a) Imputation: First we used the nscore command to correct for out of range values. This is a
transformation command.
nscore weight_0 weight_1 weight_2 weight_4 weight_12, gen(nscore)
b) Then a linear regression command was used to specify the imputation model. The dryrun was
done to check how ice would impute the missing variables. The procedure was then repeated 10
times, giving 10 imputed datasets.
2Buuren S, and Groothuis-Oudshoorn K: MICE: Multivariate imputation by chained equations in R.
Journal of statistical software2011, 45(3)
3White IR, Royston P, Wood AM: Multiple imputation using chained equations: Issues and guidance











. ice nscore1-nscore5, dryrun
#missing |
values | Freq. Percent Cum.
------------+-----------------------------------
6 | 1 0.08 0.08
7 | 23 1.91 2.00
8 | 56 4.66 6.66
9 | 138 11.48 18.14
10 | 180 14.98 33.11
11 | 234 19.47 52.58
12 | 379 31.53 84.11
. | 191 15.89 100.00
------------+-----------------------------------
Total | 1,202 100.00
Variable | Command | Prediction equation
------------+---------+-------------------------------------------------------
nscore1 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore2 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore3 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore4 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore5 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
------------------------------------------------------------------------------
End of dry run. No imputations were done, no files were created.
. ice nscore1-nscore5,saving( "C:\Imputations_data\Imputedweights.dta",replace) m(10) seed(999)
#missing |
values | Freq. Percent Cum.
------------+-----------------------------------
6 | 1 0.08 0.08
7 | 23 1.91 2.00
8 | 56 4.66 6.66
9 | 138 11.48 18.14
10 | 180 14.98 33.11
11 | 234 19.47 52.58
12 | 379 31.53 84.11
. | 191 15.89 100.00
------------+-----------------------------------
Total | 1,202 100.00
Variable | Command | Prediction equation
------------+---------+-------------------------------------------------------
nscore1 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore2 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore3 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
nscore4 | regress | nscore1 nscore2 nscore3 nscore4 nscore5
















c) Back-transformation of nscore variables to untransformed range of original data





































































Observed and Imputed Weights
Figure D.1: Distribution of observed and imputed weights at baseline, months 1, 2 and 4













2.1 Model for Baseline Renal Dysfunction
Logistic regression models specifying the prevalence odds ratio option, were estimated using STATA.











Table D.1: Crude and Adjusted Associations between covariates and severe-moderate renal
dysfunction for 1092 participants
Variable crude Adjusted
estimate (POR)a 95% CI P.value estimateb (POR) 95% CI P.value
Age years (continuous) 1.10 (1.07; 1.13) <0.001
Age category
<29 years 1.00
29-34 years 1.72 (0.54; 5.49) 0.363 2.03 (0.58; 7.75) 0.252
34-41 years 1.29 (0.39; 4.29) 0.675 1.72 (0.45; 6.60) 0.43
>41 years 6.04 (2.27; 16.05) <0.001 8.67 (2.85; 26.38) <0.001
Sex
male 1.00
female 1.30 (0.68; 2.49) 0.433 2.43 (1.11; 5.29) 0.026
Stage
I and II 1.00
III and IV 3.00 (1.42; 6.37) 0.004 2.35 (1.03; 5.37) 0.043
CD4 cells/mm3 (cont) 0.998 (0.99; 1.00) 0.237
CD4 category
<100 cells/mm3 1.00
100-200 cells/mm3 0.93 (0.42; 2.08) 0.865
>200 cells/mm3 0.48 (0.18; 1.29) 0.146
Log10 Viral Load copies/ml (cont) 1.36 (0.83; 2.21) 0.225
Viral Load category
<5 log10 copies/ml 1.00
≥5 log10 copies/ml 1.27 (0.61; 2.64) 0.519
Anaemia status
No anaemia 1.00
Anaemia c 5.40 (1.90; 15.34) 0.002 5.62 (1.67; 18.90) 0.005
aPOR: Prevalence odds ratio of moderate/severe renal dysfunction
bAdjusted for age category, sex, WHO disease stage, CD4 count and anaemia












3.1 Comparison of retained patients and those lost to follow up during the first
year on ART
Total LTFU (including death) compared to retained at month 12
Table D.2: Total patients lost to care compared to retained patients
Retained 855 (78%) Lost 237 (22%)
Median age (IQR) (years) 35 (29; 41) 33 ( 28; 40)
Age category
<29 years 228 (27%) 74 (31%)
29-34 years 195 (23%) 61 (26%)
34-41 years 224 (26%) 52 (22%)
>41 years 208 (24%) 50 (21%)
Sex
Male 300 (35%) 112 (47%)
Female 555 (65%) 125 (53%)
WHO stage n (%)
I 193 (24%) 54 (24%)
II 187 (23%) 40 (17%)
III 342 (43%) 100 (44%)
IV 84 (10%) 34 (15%)
Median CD4 cells/mm3 (IQR) 157 (92; 218) 142 (64; 219)
CD4 category n (%)
<100 cells/mm3 201 (28%) 74 (36%)
100-200 cells/mm3 284 (39%) 62 (31%)
>200 cells/mm3 239 (33%) 67 (33%)
Median Viral load (log10) copies/ml (IQR) 4.70 (4.20; 5.21) 4.83 (4.33; 5.29)
Viral load category n (%)
<5 log10 copies/ml 449 (65%) 108 (56%)
≥5 log10 copies/ml 240 (35%) 84 (44%)
Median Hemoglobin g/dL (IQR) 11.7 (10.2; 13.0) 11.5 (9.8; 12.8)
non-anemic n (%) 308 (39%) 71 (31%)
anemic n (%) 487 (61%) 155 (69%)
Median creatinine µmol/L (IQR) 64 (56; 75) 64 (56; 73)
Median weight kg (IQR) 63.2 (55.0; 71.7) 60.1 (53.7; 68.7)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 97.2 (81.3; 116.8) 96.9 (83.1; 115.5)
renal function category
moderate/severe 36 (4%) 12 (5%)
mild 291 (34%) 77 (33%)











LTFU for reasons other than death compared to retained at month 12
Table D.3: Loss to follow up (not known death) compared to retained
Retained 855 (80%) Lost 213 (20%)
Median age (IQR) (years) 35 (29; 41) 33 ( 27; 39)
Age category
<29 years 228 (27%) 70 (33%)
29-34 years 195 (23%) 53 (25%)
34-41 years 224 (26%) 46 (21%)
>41 years 208 (24%) 44 (21%)
Sex
Male 300 (35%) 101 (47%)
Female 555 (65%) 112 (53%)
WHO stage n (%)
I 193 (24%) 51 (25%)
II 187 (23%) 35 (17%)
III 342 (43%) 94 (46%)
IV 84 (10%) 24 (12%)
Median CD4 cells/mm3 (IQR) 157 (92; 218) 156 (78; 227)
CD4 category n (%)
<100 cells/mm3 201 (28%) 58 (32%)
100-200 cells/mm3 284 (39%) 57 (32%)
>200 cells/mm3 239 (33%) 64 (36%)
Median Viral load (log10) copies/ml (IQR) 4.70 (4.20; 5.21) 4.89 (4.40; 5.28)
Viral load category n (%)
<5 log10 copies/ml 449 (65%) 93 (54%)
≥5 log10 copies/ml 240 (35%) 78 (46%)
Median Hemoglobin g/dL (IQR) 11.7 (10.2; 13.0) 11.6 (10.0; 12.8)
Non-anaemic n (%) 308 (39%) 68 (34%)
Anaemic n (%) 487 (61%) 134 (66%)
Median creatinine µmol/L (IQR) 64 (56; 75) 64 (56; 73)
Median weight kg (IQR) 63.2 (55.0; 71.7) 60.12 (54.0; 68.7)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 97.2 (81.3; 116.8) 98.7 (83.4; 116.3)
Renal function category
moderate/severe 36 (4%) 8 (4%)
mild 291 (34%) 71 (33%)











Confirmed deaths on ART compared to those alive
Table D.4: Patients who died in 12 month period compared to those
alive
Alive 1068 (98%) Died 24 (2%)
Median age (IQR) (years) 34 (29; 41) 34.5 ( 30; 42.5)
Age category
<29 years 298 (27%) 4 (17%)
29-34 years 248 (23%) 8 (33%)
34-41 years 270 (25%) 6 (25%)
>41 years 252 (24%) 6 (25%)
Sex
Male 401 (38%) 11 (46%)
Female 667 (62%) 13 (54%)
WHO stage n (%)
I 244 (24%) 3 (12%)
II 222 (22%) 5 (21%)
III 436 (43%) 6 (25%)
IV 108 (11%) 10 (42%)
Median CD4 cells/mm3 (IQR) 156 (89; 219) 41.5 (7.5; 172)
CD4 category n (%)
<100 cells/mm3 259 (29%) 16 (67%)
100-200 cells/mm3 341 (38%) 5 (21%)
>200 cells/mm3 303 (33%) 3 (12%)
Median Viral load (log10) copies/ml (IQR) 4.74 (4.22; 5.22) 4.68 (4.16; 5.58)
Viral load category n (%)
<5 log10 copies/ml 542(63%) 15(71%)
≥5 log10 copies/ml 318 (37%) 6 (29%)
Median Hemoglobin g/dL (IQR) 11.7 (10.2; 13.0) 9.9 (8.95; 12.2)
non-anemic n (%) 376 (38%) 3 (13%)
anemic n (%) 621 (62%) 21 (87%)
Median creatinine µmol/L (IQR) 64 (56; 74) 65.5 (55.5; 76.5)
Median weight kg (IQR) 62.5 (54.8; 71.3) 54.2 (50.0; 67.0)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 97.2 (81.9; 116.7) 91.5 (71.6; 107.3)
Renal function category
moderate/severe 44 (4%) 4 (17%)
mild 362 (34%) 6 (25%)











3.2 Comparison of patients with missing and measured creatinine at follow-up
months
Month 12
Table D.5: Baseline characteristics: missing creatinine vs measured creatinine at
month 12
Missing 478 (44%) Measured 614 (56%)
Median age (IQR) (years) 34 (29- 41) 34 ( 29- 41)
Age category
<29 years 131 (27%) 171 (28%)
29-34 years 119 (25%) 137 (22%)
34-41 years 116 (24%) 160 (26%)
>41 years 112 (24%) 146 (24%)
Sex
Male 196 (41%) 216 (35%)
Female 282 (59%) 398 (65%)
WHO stage n (%)
I 116 (25%) 131 (23%)
II 90 (20%) 137 (24%)
III 191 (42%) 251 (43%)
IV 58 (13%) 60 (10%)
Median CD4 cells/mm3 (IQR) 155.5 (78; 218) 152 (92; 218)
CD4 category n (%)
<100 cells/mm3 131 (32%) 144 (28%)
100-200 cells/mm3 140 (34%) 206 (40%)
>200 cells/mm3 139 (34%) 167 (32%)
Median Viral load (log10) copies/ml (IQR) 4.75 (4.18; 5.22) 4.73 (4.25; 5.24)
Viral load category n (%)
<5 log10 copies/ml 251 (63%) 306 (63%)
≥5 log10 copies/ml 146 (37%) 178 (37%)
Median Hemoglobin g/dL (IQR) 11.8 (10.1; 13.0) 11.6 (10.2; 12.9)
Non-anaemic n (%) 172 (38%) 207 (37%)
Anaemic n (%) 285 (62%) 357 (63%)
Median creatinine µmol/L (IQR) 65 (56; 75) 63 (56; 74)
Median weight kg (IQR) 61.7 (55; 71.5) 63.0 (54.4; 71.0)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 95.9 (80.1; 116.3) 97.7 (82.3; 116.7)
Renal function category
moderate/severe 26 (6%) 22 (4%)
mild 168 (35%) 200 (32%)












Table D.6: Baseline characteristics: missing creatinine vs measured creatinine at
month 4
Missing 722 (66%) Measured 370 (34%)
Median age (IQR) (years) 34 (29; 41) 34 ( 29; 42)
Age category
<29 years 204 (28%) 98 (26%)
29-34 years 166 (23%) 90 (24%)
34-41 years 192 (27%) 84 (23%)
>41 years 160 (22%) 98 (27%)
Sex
Male 269 (37%) 143 (39%)
Female 453 (63%) 227 (61%)
WHO stage n (%)
I 165 (24%) 82 (24%)
II 144 (21%) 83 (24%)
III 293 (43%) 149 (43%)
IV 85 (12%) 33 (9%)
Median CD4 cells/mm3 (IQR) 163 (92; 227) 141.5 (78; 204)
CD4 category n (%)
<100 cells/mm3 164 (28%) 111 (33%)
100-200 cells/mm3 215 (36%) 131 (40%)
>200 cells/mm3 216 (36%) 90 (27%)
Median Viral load (log10) copies/ml (IQR) 4.70 (4.21; 5.23) 4.78 (4.22; 5.22)
Viral load category n (%)
<5 log10 copies/ml 354 (63%) 203 (63%)
≥5 log10 copies/ml 207 (37%) 117 (37%)
Median Hemoglobin g/dL (IQR) 11.6 (10; 12.9) 11.7 (10.4; 13.1)
Non-anaemic n (%) 244 (36%) 135 (39%)
Anaemic n (%) 428 (64%) 214 (61%)
Median creatinine µmol/L (IQR) 64 (55; 74) 65 (57; 76)
Median weight kg (IQR) 61.8 (54.1; 70.9) 63.7 (55.1; 71.7)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 97.2 (81.9; 118.3) 96.4 (80.8; 115.4)
Renal function category
moderate/severe 31 (4%) 17 (5%)
mild 239 (33%) 129 (35%)












Table D.7: Baseline characteristics: missing creatinine vs measured creatinine at
month 2
Missing 395 (36%) Measured 697 (64%)
Median age (IQR) (years) 35 (29- 41) 34 ( 29- 41)
Age category
<29 years 105 (27%) 197 (28%)
29-34 years 90 (23%) 166 (24%)
34-41 years 111 (28%) 165 (24%)
>41 years 89 (22%) 169 (24%)
Sex
Male 163 (41%) 249 (36%)
Female 232 (59%) 448 (64%)
WHO stage n (%)
I 98 (26%) 149 (23%)
II 74 (19%) 153 (23%)
III 154 (41%) 288 (44%)
IV 52 (14%) 66 (10%)
Median CD4 cells/mm3 (IQR) 161 (92; 224) 150.5 (82; 216)
CD4 category n (%)
<100 cells/mm3 86 (27%) 189 (31%)
100-200 cells/mm3 119 (37%) 227 (38%
>200 cells/mm3 116 (36%) 190 (31%)
Median Viral load (log10) copies/ml (IQR) 4.66 (4.12; 5.26) 4.78 (4.27; 5.22)
Viral load category n (%)
<5 log10 copies/ml 194 (65%) 363 (62%)
≥5 log10 copies/ml 104 (35%) 220 (38%)
Median Hemoglobin g/dL (IQR) 11.8 (10.2; 13.1) 11.6 (10.1; 12.9)
Non-anaemic n (%) 147 (40%) 232 (36%)
Anaemic n (%) 222 (60%) 420 (64%)
Median creatinine µmol/L (IQR) 64 (56; 74) 64 (56; 74)
Median weight kg (IQR) 62.2 (54.5; 70.6) 62.7 (54.4; 71.6)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 97.1 (82.6; 114.9) 97.2 (81.0; 118.2)
Renal function category
moderate/severe 19 (5%) 29 (4%)
mild 130 (33%) 238 (34%)












Table D.8: Baseline characteristics: missing creatinine vs measured creatinine at
month 1
Missing 451 (41%) Measured 641 (59%)
Median age (IQR) (years) 35 (29; 41) 34 ( 29; 41)
Age category
<29 years 132 (29%) 170 (26%)
29-34 years 91 (20%) 165 (26%)
34-41 years 117 (26%) 159 (25%)
>41 years 111 (25%) 147 (23%)
Sex
Male 172 (38%) 240 (37%)
Female 279 (62%) 401 (63%)
WHO stage n (%)
I 110 (26%) 137 (22%)
II 89 (21%) 138 (23%)
III 171 (40%) 271 (45%)
IV 55 (13%) 63 (10%)
Median CD4 cells/mm3 (IQR) 155.5 (84; 221) 154 (85; 217)
CD4 category n (%)
<100 cells/mm3 112 (30%) 163 (30%)
100-200 cells/mm3 139 (37%) 207 (37%)
>200 cells/mm3 123 (33%) 183 (33%)
Median Viral load (log10) copies/ml (IQR) 4.79 (4.21; 5.29) 4.70 (4.22; 5.21)
Viral load category n (%)
<5 log10 copies/ml 207 (61%) 350 (65%)
≥5 log10 copies/ml 132 (39%) 192 (35%)
Median Hemoglobin g/dL (IQR) 11.7 (10.1; 12.8) 11.7 (10.2; 13.1)
Non-anaemic n (%) 149 (35%) 230 (39%)
Anaemic n (%) 276 (65%) 366 (61%)
Median creatinine µmol/L (IQR) 64 (56; 76) 64 (56; 73)
Median weight kg (IQR) 62.3 (54.4; 72.3) 62.6 (54.5; 70.9)
Median eGFR ml/min/1.73 m2 [CG] (IQR) 96.5 (81.8; 116.5) 97.9 (81.3; 116.7)
Renal function category
moderate/severe 21 (4%) 27 (4%)
mild 152 (34%) 216 (34%)
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The legends should be included in the main manuscript text file at the end of the document, 
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should not be used to indicate numerical values. Color and shading may not be used; parts of 
the table can be highlighted using symbols or bold text, the meaning of which should be 
explained in a table legend. Tables should not be embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a landscape page can be uploaded separately as 
additional files. Additional files will not be displayed in the final, laid-out PDF of the article, 
but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or 
comma separated values (.csv). As with all files, please use the standard file extensions. 
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such as patient consent forms, certificates of language editing, or revised versions of the main 
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aidsrestherapy@gmail.com, quoting the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should be included as 
additional files. Since many weblinks and URLs rapidly become broken, AIDS Research and 
Therapy requires that supporting data are included as additional files, or deposited in a 
recognized repository. Please do not link to data on a personal/departmental website. The 
maximum file size for additional files is 20 MB each, and files will be virus-scanned on 
submission.  
Additional files can be in any format, and will be downloadable from the final published 
article as supplied by the author. We recommend CSV rather than PDF for tabular data. 
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geographic data files (KML).  
If additional material is provided, please list the following information in a separate section 
of the manuscript text: 
 File name (e.g. Additional file 1) 
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx 
(including name and a URL of an appropriate viewer if format is unusual) 
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 Description of data 
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Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be 
viewable using free or widely available tools. The following are examples of suitable 
formats. 
 Additional documentation  
o PDF (Adode Acrobat) 
 Animations  
o SWF (Shockwave Flash) 
 Movies  
o MP4 (MPEG 4) 
o MOV (Quicktime) 
 Tabular data  
o XLS, XLSX (Excel Spreadsheet) 
o CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they 
will be browsable from within the full text HTML version of the article. In order to do this, 
please follow these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in the root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than 
"/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or "C:\Documents 
and Settings\username\My Documents\mini-website\images\picture.jpg") and no link 
is longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure that the 
most commonly used browsers (Internet Explorer and Firefox) are able to view all 
parts of the mini-website without problems, it is ideal to check this on a different 
machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that 
index.html is in the root of the ZIP, and that the file has .zip extension, then submit as 
an additional file with your article. 
Style and language 
General 
Currently, AIDS Research and Therapy can only accept manuscripts written in English. 
Spelling should be US English or British English, but not a mixture. 












AIDS Research and Therapy will not edit submitted manuscripts for style or language; 
reviewers may advise rejection of a manuscript if it is compromised by grammatical errors. 
Authors are advised to write clearly and simply, and to have their article checked by 
colleagues before submission. In-house copyediting will be minimal. Non-native speakers of 
English may choose to make use of a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our 
page on Writing titles and abstracts for scientific articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. 
American Scientist also provides a list of resources for science writing. For more detailed 
guidance on preparing a manuscript and writing in English, please visit the BioMed Central 
author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first 
used and a list of abbreviations can be provided following the main manuscript text.
Typography 
 Please use double line spacing.
 Type the text unjustified, without hyphenating words at line breaks.
 Use hard returns only to end headings and paragraphs, not to rearrange lines.
 Capitalize only the first word, and proper nouns, in the title.
 All pages should be numbered.
 Use the AIDS Research and Therapy reference format.
 Footnotes are not allowed, but endnotes are permitted.
 Please do not format the text in multiple columns.
 Greek and other special characters may be included. If you are unable to reproduce a
particular special character, please type out the name of the symbol in full. Please
ensure that all special characters used are embedded in the text, otherwise they 
will be lost during conversion to PDF.
Units 
SI units should be used throughout (liter and molar are permitted, however). 
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